A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Reference |
|---|
| "Osteosclerotic multiple myeloma is very rare." | ( Felder, M; Keiser, G; Wirth, W, 1979) |
| "3 cases of multiple myeloma are still living 44 months after the onset of symptoms." | ( Mikami, M; Oikawa, K; Onodera, S; Otaki, M; Sato, I, 1975) |
| "Multiple myeloma is characterized by an increased susceptibility to infections and to other malignancies." | ( Drivsholm, A; Klarlund, K; Mansa, B; Moesgaard, F; Nielsen, H; Nielsen, HJ; Tvede, N, 1990) |
| "Multiple myeloma is a disease with a high initial chemotherapeutic response but virtually no cures due to emergence of drug resistance." | ( Alberts, DS; Cress, AE; Dalton, WS; Durie, BG; Gerlach, JH, 1986) |
| "A patient with multiple myeloma is described who developed severe intrahepatic cholestasis secondary to hepatic deposition of amyloid." | ( Calomeni, JA; Smith, JR, 1985) |
| "Multiple myeloma is almost always osteolytic, with very little new bone formation and extensive osteoclast activity related to osteoclast activating factor, whereas skeletal uptake of 99Tcm-diphosphonate seems to be related mainly to osteoblastic process." | ( Calzolari, F; Cervi, PM; Feggi, LM; Scutellari, PN; Spanedda, R, 1984) |
| "Multiple myeloma is a disease characterized by the proliferation of malignant plasma cells, the over-production of a monoclonal immunoglobulin (paraprotein) and the subsequent depression of the other normal immunoglobulins." | ( Dutcher, JP; Wiernik, PH, 1984) |
| "Multiple myeloma is one of the few malignancies with a distinct tumor marker, the myeloma protein." | ( Hoogstraten, B, 1982) |
| "Multiple myeloma is basically an incurable cancer." | ( Belch, AR; Pilarski, LM, 1994) |
| "Multiple myeloma is considered to be a drug responsive disease; however, there is no cure for this disease and virtually all patients will develop drug resistance." | ( Bonnet, JD; Crowley, JJ; Dalton, WS; Grogan, TM; Laufman, LR; Salmon, SS; Weiss, GR, 1995) |
| "Multiple myeloma is characterized by bone disease including osteoporosis, osteolytic lesions, pathological fractures and hypercalcaemia leading to pain, immobilization and decrease in the quality of life." | ( Jantunen, E; Laakso, M; Lahtinen, R, 1995) |
| "Multiple myeloma is very frequently associated with anaemia which has the character of hypo-proliferative anaemia of chronic diseases." | ( Adam, Z; Hájek, R; Hejlová, N; Krahulová, M; Spelda, S; Tomíska, M; Vorlícek, J, 1995) |
| "Patients with multiple myeloma are at increased risk for bacterial infection." | ( Bennett, JM; Oken, MM; Pomeroy, C; Weisdorf, D, 1996) |
| "The occurrence of multiple myeloma is described in a patient receiving phenytoin (diphenylhydantoin) for 43 years." | ( Dobashi, H; Inada, T; Kanoh, T, 1996) |
| "Multiple myeloma is very frequently associated with anemia which has the character of hypoproliferative anemia of chronic diseases." | ( Adam, Z; Hájek, R; Hejlová, N; Krahulová, M; Spelda, S; Tomíska, M; Vorlícek, J, 1995) |
| "Multiple myeloma is a plasma cell malignancy which is generally incurable in spite of a high initial response to chemotherapy." | ( Bellamy, WT; Ellsworth, L; Grogan, TM; Odeleye, A; Peng, YM; Weinstein, RS; Xu, MJ, 1995) |
| "Multiple myeloma is a very devastating cancer with a high capacity to destroy bone matrix." | ( Akhoundi, C; Amiot, M; Barillé, S; Bataille, R; Collette, M; Harousseau, JL; Mellerin, MP; Rapp, MJ, 1997) |
| "One reason is that multiple myeloma is usually grouped with other lymphopoietic cancers in the analysis." | ( Raabe, GK; Wong, O, 1997) |
| "Multiple myeloma is a plasma cell malignancy often associated with destructive skeletal lesions." | ( Fay, AM; Fountain, KS; Leib, ML, 1998) |
| "Multiple myeloma is a neoplastic proliferation of plasma cells." | ( Halgren, RG; Krett, NL; Pillay, S; Rosen, ST; Traynor, AE; Zell, JL, 1997) |
| "Multiple myeloma is a disorder of the bone marrow that is associated with bone pain and osteolytic lesions." | ( Dranitsaris, G, 1999) |
| "Multiple myeloma is associated with unbalanced bone remodeling causing lytic bone lesions." | ( Børset, M; Hjertner, O; Hjorth-Hansen, H; Seidel, C; Sundan, A; Torgersen, ML; Waage, A, 1999) |
| "Multiple myeloma is the second most common hematologic malignancy, with approximately 15,000 new cases each year in the United States." | ( Berenson, JR; Sjak-Shie, NN; Vescio, RA, 2000) |
| "Multiple myeloma is still an incurable disease." | ( Egerer, G; Goldschmidt, H; Ho, AD, 2000) |
| "Multiple myeloma is a B-cell malignancy characterized by proliferation of neoplastic plasma cells." | ( Butch, AW; Flick, JT; Pappas, AA; Yeh, YA, 2000) |
| "Multiple myeloma is associated with the development of osteolytic bone disease characterized by a disruption to normal bone resorption and bone formation." | ( Croucher, PI; Karadag, A; Scutt, AM, 2000) |
| "Multiple myeloma is an incurable disease and after several lines of chemotherapy, patients enter a phase in which no standard treatment options are available." | ( Bloem, AC; de Weerdt, O; Hagenbeek, A; Lokhorst, HM; van de Donk, NW; Veth, G, 2001) |
| "with progressive multiple myeloma are associated with unfavorable parameters of response and survival but nevertheless predict for response to Thal therapy." | ( Benner, A; Egerer, G; Goldschmidt, H; Hillengass, J; Ho, AD; Kraemer, A; Moehler, T; Neben, K, 2001) |
| "Multiple myeloma is a relatively common hematologic malignancy with no definitive treatment available." | ( Jákó, J; Mikala, G; Vályi-Nagy, I, 2001) |
| "Multiple myeloma is a B-cell malignancy characterized by the accumulation of plasma cells in the bone marrow and the development of osteolytic bone disease." | ( Asosingh, K; Brabbs, AC; Croucher, PI; Dunstan, CR; Hijzen, A; Holen, I; Lippitt, J; Perry, M; Russell, GR; Shipman, CM; Skerry, TM; van Beek, EJ; Van Camp, B; Vanderkerken, K, 2001) |
| "Multiple myeloma is a clonal B-cell tumor of slowly proliferating plasma cells within the bone marrow." | ( Hussein, MA; Juturi, JV; Lieberman, I, 2002) |
| "Multiple myeloma is characterized by the clonal proliferation of malignant plasma cells in the bone marrow associated with bone loss, renal disease, and immunodeficiency." | ( Hussein, MA, 2001) |
| "Additionally, multiple myeloma is primarily a disease of the elderly, many of whom cannot tolerate aggressive chemotherapy." | ( Hussein, MA, 2002) |
| "Multiple myeloma is one of the most common haematologic malignancies." | ( Kmonícek, M; Kopecký, O; Krejsek, J; Maisnar, V; Malý, J; Tousková, M, 2002) |
| "Multiple myeloma is incurable with standard chemotherapy." | ( Niederwieser, D; Pönisch, W, 2002) |
| "Multiple myeloma is an incurable plasma cell malignancy that accounts for 10% of all hematologic cancers." | ( Gertz, MA; Greipp, PR; Kyle, RA; Rajkumar, SV, 2002) |
| "Multiple myeloma is a malignancy of plasma cells and is characterized by increased marrow angiogenesis." | ( Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, S; Greipp, PR; Hayman, S; Iturria, N; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2002) |
| "Multiple myeloma is a malignant proliferation of plasma cells which fail to undergo apoptosis." | ( Batchu, RB; Ding, L; Iyer, R; Munshi, NC; Naugler, S; Shammas, MA, 2003) |
| "Multiple myeloma is characterized by the growth of plasma cells in the bone marrow and the development of osteolytic bone disease." | ( Croucher, PI; De Hendrik, R; Green, J; Hijzen, A; Lippitt, J; Perry, MJ; Shipman, CM; Van Camp, B; Van Marck, E; Vanderkerken, K, 2003) |
| "Multiple myeloma is characterized by bone destruction mediated by osteoclastic bone resorption." | ( Niesvizky, R, 2003) |
| "The discovery that multiple myeloma is associated with new vessel formation and is correlated with survival and proliferation led initially to the use of thalidomide for patients with relapsed or refractory disease." | ( Schey, SA, 2002) |
| "Multiple myeloma is a non-curable haematological disease involving transformed plasma cells." | ( Baumgart, J; Dayyani, F; Emmerich, B; Jahrsdörfer, B; Meinhardt, G; Schmidmaier, R, 2003) |
| "Appearance of multiple myeloma is unusual in this case." | ( Bagó, A; Baló-Banga, JM; Fúrész, J; Kis, M; Schweitzer, K; Vajda, A, 2003) |
| "Multiple myeloma is the second most common hematologic malignancy with currently no definitive treatment available." | ( Jákó, J; Mikala, G; Vályi-Nagy, I, 2004) |
| "Multiple myeloma is a malignant disease of plasma cells that manifests as one or more of lytic bone lesions, monoclonal protein in the blood or urine, and disease in the bone marrow." | ( Powles, R; Sirohi, B, 2004) |
| "Multiple myeloma is a plasma cell malignancy characterized by the development of osteolytic lesions leading to bone pain, pathologic fractures, and hypercalcemia." | ( Chen, D; Doran, PM; Facteau, SM; Khosla, S; Ludvigson, JM; Riggs, BL; Russell, SJ; Turner, RT, 2004) |
| "Multiple myeloma is a severe plasma dyschrasia with no known treatment or cure, even bone marrow transplantation." | ( Altschuler, EL; Kast, RE, 2004) |
| "The diagnosis of multiple myeloma is based on an immunobinding of plasmatic proteins." | ( Cheour, I; Elleuch, M; Hamza, S; Landolsi, F; Meddeb, N; Sahli, H; Sellami, S, 2004) |
| "Multiple myeloma is associated with the development of a devastating bone disease mediated by increased osteoclastic activity." | ( Croucher, PI; De Leenheer, E; Mueller, GS; Vanderkerken, K, 2004) |
| "Multiple myeloma is a B-cell cancer characterized by the proliferation of malignant plasma cells in the bone marrow, increased angiogenesis, and the development of osteolytic bone disease." | ( Asosingh, K; Blacher, S; Carron, C; Croucher, PI; De Bruyne, E; De Leenheer, E; De Raeve, H; Devy, L; Noël, A; Van Camp, B; Van Riet, I; Van Valckenborgh, E; Vanderkerken, K, 2004) |
| "Multiple myeloma is essentially an incurable malignancy and it is therefore of great interest to develop new therapeutic approaches." | ( Bernstein, SH; Phipps, RP; Ray, DM, 2004) |
| "Multiple myeloma is a fatal B cell malignancy characterized by the accumulation of plasma cells within the bone marrow." | ( Amiot, M; Bataille, R; Gomez-Bougie, P, 2004) |
| "Multiple myeloma is associated with a susceptibility to bacterial infections, specifically for encapsulated organisms such as Streptococcus pneumoniae." | ( Cooper, DL; Costa, DB; Shin, B, 2004) |
| "For instance, multiple myeloma is characterized by frequent karyotypic instability at the earliest stage, progressing to extreme genetic abnormalities as the disease progresses." | ( Cherry, JM; Farrar, WL; Hodge, DR; Munroe, DJ; Peng, B; Pompeia, C; Thomas, SB; Xiao, W, 2005) |
| "Multiple myeloma is a malignancy of plasma cells with osteolytic bone destruction." | ( Hamano, T; Kitano, M; Ogata, A; Sano, H; Sekiguchi, M, 2005) |
| "Multiple myeloma is characterized by the accumulation of terminally differentiated B cells in the bone marrow, due to increased proliferation and restricted apoptosis of the myelomatous clone." | ( Carvajal-Vergara, X; Esparís-Ogando, A; Gutiérrez, N; López-Pérez, R; Mateo, G; Montero, JC; Pandiella, A; Parmo-Cabañas, M; San Miguel, JF; Tabera, S; Teixidó, J, 2005) |
| "Multiple myeloma is an incurable B-cell malignancy requiring new therapeutic strategies." | ( Gauduchon, J; Gouilleux, F; Maillard, S; Marsaud, V; Renoir, JM; Sola, B, 2005) |
| "Multiple myeloma is characterized by an accumulation of malignant plasma cells in the bone marrow." | ( Baykov, V; Brabrand, S; Børset, M; Holt, RU; Rø, TB; Sundan, A; Waage, A, 2005) |
| "Multiple myeloma is a slowly proliferating B-cell malignancy that accumulates apoptosis-resistant and replication-quiescent cell populations, posing a challenge for current chemotherapeutics that target rapidly replicating cells." | ( Gandhi, V; Ghias, K; Krett, NL; Ma, C; Platanias, LC; Rosen, ST, 2005) |
| "In most cases multiple myeloma is an incurable plasma cell malignancy." | ( Dimopoulos, MA; Rahemtulla, A; Terpos, E, 2005) |
| "Multiple myeloma is a clonal malignancy of plasma cells that invariably progresses to a chemoresistant state." | ( Bahlis, NJ; Boise, LH; Gerson, SL; Koc, ON; Lee, K; Miao, Y, 2005) |
| "Multiple myeloma is a B-cell malignancy for which no curative therapies exist to date, despite enormous research efforts." | ( Altun, M; Anderson, KC; Galardy, PJ; Hideshima, T; Kessler, BM; LeBlanc, R; Ploegh, HL; Shringarpure, R, 2005) |
| "Human multiple myeloma is a presently incurable hematologic malignancy, and novel biologically based therapies are urgently needed." | ( Anderson, KC; Carver, B; Chang, Y; Chauhan, D; He, D; Hideshima, T; Li, G; Mitsiades, N; Neri, P; Podar, K; Richardson, P; Schindler, J, 2005) |
| "Multiple myeloma is the second most prevalent and mostly fatal hematologic cancer." | ( Adam, Z; Gregora, E; Hájek, R; Klener, P; Maisnar, V; Schutzova, M; Scudla, V; Spicka, I; Straub, J; Vytrasová, M, 2005) |
| "Multiple myeloma is a plasma cell malignancy that remains incurable with current treatment approaches including high-dose therapy and autologous stem cell transplantation." | ( Kumar, S; Rajkumar, SV, 2005) |
| "Multiple myeloma is characterized by the accumulation of clonal malignant plasma cells in the bone marrow, which stimulates bone destruction by osteoclasts and reduces bone formation by osteoblasts." | ( Abdallah, BM; Andersen, TL; Boissy, P; Delaissé, JM; Kassem, M; Plesner, T, 2005) |
| "Multiple myeloma is a tumor of somatically mutated, isotype-switched plasma cells that accumulate in the bone marrow leading to bone destruction and bone marrow failure." | ( Bergsagel, PL; Kuehl, WM, 2005) |
| "Multiple myeloma is a B-cell malignancy characterized by an excess of monotypic plasma cells in the bone marrow." | ( Anderson, KC, 2005) |
| "Multiple myeloma is a highly radiosensitive skeletal malignancy, but bone-seeking radionuclides have not yet found their place in disease management." | ( Dispenzieri, A; Geyer, SM; Goel, A; Greiner, S; Peng, KW; Russell, SJ, 2006) |
| "Multiple myeloma is an incurable bone marrow cancer, the treatment of which is notoriously difficult." | ( García-Sanz, R, 2006) |
| "Multiple myeloma is an incurable disease for the majority of patients, therefore requiring new biological targeted therapies." | ( Bauer, K; Cheng, X; Fandy, TE; Shankar, S; Shaughnessy, J; Srivastava, RK; Takebe, N; Tricot, G; Wu, S, 2006) |
| "Multiple myeloma is characterized by an accumulation of plasma cells in bone marrow." | ( Dmoszynska, A; Grzasko, N; Klimek, P; Podhorecka, M, 2006) |
| "Multiple myeloma is a blood disease that is often easy to diagnose, relying on a combination of an excessive medullary plasmacytosis, a serum and/or urinary monoclonal immunoglobulin and one or several signs of organ involvement (anemia, renal failure, bone lesions, hypercalcaemia, infections)." | ( Coiteux, V; Facon, T; Leleu, X, 2006) |
| "Multiple myeloma is a malignant process of the plasma cell." | ( Hussein, MA, 2006) |
| "Multiple myeloma is characterized by accumulation of monoclonal plasma cells in the bone marrow and progression of lytic bone lesions." | ( Abe, M, 2006) |
| "The M proteins of multiple myeloma are positively charged." | ( Fredman, B; Sachs, J, 2006) |
| "Multiple myeloma is a disease in which angiogenesis is postulated to be a target for therapy." | ( Dong, RP; Eisenhauer, E; Kovacs, MJ; Marcellus, D; Mathews, S; Meyer, RM; Reece, DE, 2006) |
| "Multiple myeloma is a clonal disorder of plasma cells which is considered incurable with currently available therapies." | ( Hussein, MA; Kalmadi, SR, 2006) |
| "Multiple myeloma is characterized by the proliferation of clonal plasma cells that have a heterogeneous expression of various cell surface markers, precluding successful use of monoclonal antibodies for therapeutic targeting of the tumor cell." | ( Greipp, PR; Haug, JL; Kimlinger, TK; Kline, MP; Kumar, SK; Rajkumar, SV; Timm, MM, 2006) |
| "Multiple myeloma is a treatable but not necessarily a curable plasma-cell cancer." | ( Jagannath, S; Mazumder, A, 2006) |
| "Multiple myeloma is characterized by increased osteoclast activity that results in bone destruction and lytic lesions." | ( Anderson, G; Elliott, G; Feng, R; Lentzsch, S; Leoni, L; Mapara, MY; Roodman, GD; Xiao, G, 2007) |
| "Multiple myeloma is an incurable hematologic malignancy characterized by increased bone marrow angiogenesis and extensive lytic bone disease." | ( Dewar, AL; Farrugia, AN; Gronthos, S; Horvath, N; Martin, SK; To, LB; Zannettino, AC, 2006) |
| "Multiple myeloma is a low malignant, non-Hodgkin's lymphoma, which is characterised by infiltration of the bone marrow by clonal prolifaration of atypical plasma cells." | ( Florschütz, A; Kachel, R; Knolle, J; Schelle, M; Schreiber, C; Schreiber, J, 2006) |
| "Corneal deposits in multiple myeloma are well described in the literature, but there are few reports regarding the prognosis and visual function after penetrating keratoplasty." | ( Font, RL; Matoba, AY; Prabhakaran, VC, 2006) |
| "Multiple myeloma is a malignant disease with high incidence in middle-aged and old-aged population." | ( Bo, J; Da, WM; Gao, CJ; Huang, WR; Jing, Y; Li, R; Wang, QS; Wu, XX; Yu, L; Zhang, YZ, 2006) |
| "Serous effusions in multiple myeloma are uncommon but a myelomatous pleural effusion occurring in these patients is extremely rare." | ( Advani, SH; Ghosh, S; Gopal, R, 2006) |
| "Cure for multiple myeloma is rare; the success of treatment is measured by response, and length of remissions and survival." | ( Boccadoro, M; Cavenagh, J; Dicato, M; Harousseau, JL; Ludwig, H; San Miguel, J; Sonneveld, P, 2006) |
| "Multiple myeloma is an incurable plasma cell neoplasia characterized by the production of large amounts of monoclonal immunoglobulins." | ( Burger, R; Gramatzki, M; Hahn, S; Herrmann, K; Herrmann, M; Jäck, HM; Meister, S; Neubert, K; Schreiber, S; Schubert, U; Voll, RE; Wilhelm, S, 2007) |
| "Intracranial multiple myeloma is uncommon." | ( Bocchia, M; Cerase, A; Fabbri, A; Gozzetti, A; Lauria, F; Pirrotta, MT; Tarantino, A, 2007) |
| "Multiple myeloma is a heterogeneous disease with complex genetics, including a variety of primary and secondary genetic events that contribute to disease pathogenesis." | ( Bergsagel, PL, 2007) |
| "Multiple myeloma is currently an incurable cancer of plasma B cells often characterized by overproduction of abnormally high quantities of a patient-specific, clonotypic immunoglobulin "M-protein." | ( Ben-Dov, E; Cahan, R; Cohen, S; Firer, MA; Nisnevitch, M; Zaritsky, A, 2007) |
| "Multiple myeloma is a fatal hematological disease caused by malignant transformation of plasma cells." | ( Baumann, P; Emmerich, B; Gaul, L; Mandl-Weber, S; Schmidmaier, R, 2008) |
| "Multiple myeloma is the most common plasma cell neoplasm, with abnormal clonal proliferation of B cells in bone marrow." | ( Nguyen, BD; Wiesenthal, AA, 2007) |
| "Multiple myeloma is one of the incurable B-cell malignancies that continues to relapse with current treatment modalities, and the duration to progression becomes shorter in patients who repeatedly receive chemotherapy." | ( Tobinai, K, 2007) |
| "Patients with multiple myeloma are at risk for bacterial infections such as Streptococcus pneumoniae, Haemophilus influenzae, and Escherichia coli." | ( Yoshida, M, 2007) |
| "Multiple myeloma is also one of the major therapeutic targets for using molecular based technology." | ( Takatoku, M, 2007) |
| "Multiple myeloma is still not curable and drug combination strategies are currently being evaluated in order to achieve high remission rates with tolerable toxicity." | ( Baumann, P; Mandl-Weber, S; Oduncu, F; Schmidmaier, R, 2008) |
| "Multiple myeloma is the second most common haematological malignancy." | ( Davies, FE; Morgan, GJ; Srikanth, M, 2008) |
| "Multiple myeloma is characterized by the accumulation and dissemination of malignant plasma cells in the bone marrow." | ( Baykov, V; Børset, M; Fagerli, UM; Holt, RU; Hov, H; Rø, TB; Sundan, A; Waage, A, 2008) |
| "A case of multiple myeloma is reported in which the bone marrow contained sheets of histiocytes with light microscopic features mimicking Gaucher cells." | ( Banerjee, SS; Eyden, B; Roy, A; Shenjere, P, 2008) |
| "Multiple myeloma is a neoplasm of mature and immature plasma cells, it remains an incurable disease using conventional chemotherapy and increasing aggressive approaches." | ( Ke, XY; Wang, LH; Wang, YF; Yang, YH, 2008) |
| "Multiple myeloma is associated with a high risk of infections." | ( Melsvik, D; Mølle, I; Nyvold, CG; Ostergaard, M, 2008) |
| "Multiple myeloma is an incurable B-cell malignancy requiring new therapeutic strategies in clinical settings." | ( Ikeda, Y; Kizaki, M; Nakazato, T; Sagawa, M; Uchida, H, 2008) |
| "Multiple myeloma is a malignancy of plasma cells that remains incurable and almost all patients will eventually require some form of salvage therapy." | ( Atkins, H; Belch, AR; Canning, LA; Kovacs, MJ; LeBlanc, R; Leitch, HA; Reece, DE; Voralia, M; White, D, 2008) |
| "- Multiple myeloma is a malignant plasma-cell proliferative disorder, the second most common haematologic cancer." | ( Cevreska, L; Genadieva-Stavric, S; Georgievski, B; Karadzova-Stojanoska, A; Pivkova, A; Stankovic, S; Stojanoski, Z; Stojanovic, A, 2008) |
| "Multiple myeloma is an incurable plasma cell malignancy." | ( Chen, X; Dong, H; Gao, G; Gu, H, 2008) |
| "Human multiple myeloma is a presently incurable hematological malignancy and novel biologically based therapies are urgently needed." | ( Huang, J; Jin, J; Pan, HZ; Yang, M, 2008) |
| "Multiple myeloma is still an incurable disease, most commonly occurring in the elderly." | ( Abe, M; Amou, H; Harada, T; Hashimoto, T; Hiasa, M; Kitazoe, KI; Matsumoto, T; Nakano, A; Oda, A; Ozaki, S; Takeuchi, K, 2009) |
| "Multiple myeloma is exquisitely sensitive to proteosome or NF-kappaB pathway inhibition." | ( Keats, JJ; Mao, X; Palmer, SE; Schimmer, AD; Schmidt, J; Shi, CX; Stewart, AK; Tiedemann, RE; Zhu, YX, 2009) |
| "Multiple myeloma is still an incurable disease." | ( Dmoszyńska, A, 2008) |
| "Multiple myeloma is an incurable disease with heterogeneous clinical behavior." | ( Dawson, MA; Donovan, M; Hertzberg, M; Horvath, N; McLean, CA; Monaghan, K; Opat, SS; Prince, HM; Roberts, AW; Spencer, A; Taouk, Y; Zammit, M, 2009) |
| "Multiple myeloma is an incurable plasma cell malignancy." | ( Cohen, S; Haimovich, J; Hollander, N, 2009) |
| "Multiple myeloma is still an incurable disease; therefore, new therapeutics are urgently needed." | ( Adam, C; Baumann, P; Bumeder, I; Mandl-Weber, S; Oduncu, F; Schmidmaier, R; Völkl, A, 2009) |
| "Multiple myeloma is still incurable." | ( Baumann, P; Franke, D; Hagemeier, H; Mandl-Weber, S; Schmidmaier, R, 2009) |
| "Multiple myeloma is a malignancy of terminally differentiated plasma cells and is incurable in the majority of the patients." | ( Heider, U; Jakob, C; Kaiser, M; Lamottke, B; Mieth, M; Sezer, O; von Metzler, I, 2009) |
| "Multiple myeloma is characterised by clonal proliferation of malignant plasma cells, and mounting evidence indicates that the bone marrow microenvironment of tumour cells has a pivotal role in myeloma pathogenesis." | ( Anderson, KC; Breitkreutz, I; Podar, K; Raab, MS; Richardson, PG, 2009) |
| "Multiple myeloma is the most common indication for high-dose chemotherapy with autologous stem cell support (ASCT) in North America today." | ( Anderson, KC; Attal, M; Barlogie, B; Bensinger, W; Blade, J; Boccadoro, M; Cavo, M; Chen, W; Comenzo, RL; Dimopoulos, MA; Dispenzieri, A; Durie, BG; Einsele, H; Gertz, M; Giralt, S; Hajek, R; Harousseau, JL; Jagannath, S; Joshua, D; Kumar, S; Kyle, R; Lonial, S; Ludwig, H; Mateos, MV; Merlini, G; Morgan, G; Munshi, NC; Niesvizky, R; Palumbo, A; Powles, R; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Shimizu, K; Sonneveld, P; Stadtmauer, EA; Tosi, P; Turesson, I, 2009) |
| "Multiple myeloma is a malignant B-cell neoplasm that involves the skeleton in approximately 80% of the patients." | ( Croockewit, S; de Rooy, JW; Koedam, E; Lütje, S; Oyen, WJ; Raymakers, RA, 2009) |
| "Multiple myeloma is an incurable hematologic cancer affecting over 50,000 Americans." | ( Stadtmauer, EA, 2004) |
| "Multiple myeloma is characterized by increased bone marrow neovascularization driven in part by vascular endothelial growth factor (VEGF)." | ( Adjei, AA; Haug, JL; Kimlinger, TK; Kumar, S; Rajkumar, SV; Ramakrishnan, V; Timm, M; Wellik, LE; Witzig, TE, 2010) |
| "Multiple myeloma is a malignancy of plasma cells." | ( Kang, SH; Kim, SK; Kim, TS; Kim, YI; Kwon, HW; Lee, JW; Lee, SM, 2010) |
| "IgA multiple myeloma is the second most frequent variant of multiple myeloma." | ( Kumiega, B; Skotnicki, AB; Wolska-Smoleń, T, 2009) |
| "Multiple myeloma is a heterogeneous group of plasma cell neoplasms that primarily involve bone marrow but also may occur in the soft tissue." | ( Christensen, CR; Crim, JR; Hanrahan, CJ, 2010) |
| "Multiple myeloma is one of the most common hematological malignancies and accounts for significant morbidity and mortality." | ( Carty, F; Murray, JG; Shortt, CP, 2010) |
| "Multiple myeloma is an incurable clonal B-cell malignancy with terminally differentiated plasma cells that accounts for 1% of all malignancies in the United States." | ( Destian, S; Hwang, BJ; Jagannath, S; Mazumder, A; Méndez, CE; Vesole, DH, 2010) |
| "Multiple myeloma is an incurable hematological malignancy." | ( Chen, Y; Li, R; Liu, Y; Wen, L; Zeng, L; Zeng, R; Zhang, C; Zhao, F, 2010) |
| "Multiple myeloma is an immunologically relevant disease, which subverts and suppresses immunity, but that may also be amenable to immunological control." | ( Fielding, K; Neeson, P; Quach, H; Ritchie, DS, 2010) |
| "Advanced multiple myeloma is typically accompanied by osteolytic bone lesions resulting from heightened osteolytic activity of osteoclasts and decreased rates of osteogenesis by osteoblasts." | ( Berenson, JR, 2010) |
| "Multiple myeloma is clinically heterogeneous and risk stratification is vital for prognostication and informing treatment decisions." | ( Choo, C; Goh, YT; Hwang, W; Lao, ZT; Lau, LC; Lee, LH; Lee, YS; Lim, A; Lim, TH; Premalatha, P; Su, S; Tan, D; Teoh, G; Wee, HC; Wee, N; Yap, KC, 2010) |
| "Multiple myeloma is a hematologic malignancy characterized by growth of malignant plasma cells in the bone marrow." | ( Dhodapkar, MV; Richter, J, 2011) |
| "Multiple myeloma is characterized by ongoing autophagy as a consequence of constitutive immunoglobulin production, which creates the need for efficient transfer and disposal of misfolded or unfolded proteins." | ( Boise, LH; Lonial, S, 2011) |
| "Multiple myeloma is the second most prevalent haematological malignancy and is incurable." | ( Anderson, KC; Armand, P; Bagshaw, M; Banwait, R; Chuma, S; Dollard, A; Ghobrial, IM; Harris, B; Jakubowiak, AJ; Kunsman, J; Laubach, J; Leduc, R; Maiso, P; Munshi, NC; Poon, T; Richardson, PG; Roccaro, A; Rodig, S; Sam, A; Schlossman, R; Vij, R; Warren, D; Weller, E, 2011) |
| "Multiple myeloma is an incurable malignancy of plasma cells, and its pathogenesis is poorly understood." | ( Adli, M; Ahmann, GJ; Anderson, KC; Ardlie, KG; Auclair, D; Baker, A; Bergsagel, PL; Bernstein, BE; Brunet, JP; Carpten, J; Chapman, MA; Cibulskis, K; Drier, Y; Fonseca, R; Gabriel, SB; Garraway, LA; Getz, G; Golub, TR; Hahn, WC; Harview, CL; Hofmeister, CC; Jagannath, S; Jakubowiak, AJ; Keats, JJ; Krishnan, A; Lander, ES; Lawrence, MS; Levy, J; Liefeld, T; Lonial, S; Mahan, S; Meyerson, M; Mfuko, B; Monti, S; Onofrio, R; Perkins, LM; Pugh, TJ; Rajkumar, SV; Ramos, AH; Schinzel, AC; Siegel, DS; Sivachenko, A; Sougnez, C; Stewart, AK; Trent, J; Trudel, S; Vij, R; Voet, D; Winckler, W; Zimmerman, T, 2011) |
| "Multiple myeloma is a fatal B cell neoplasm often resulting in focal and in some cases more diffuse destruction of bone." | ( Kupisiewicz, K, 2011) |
| "Multiple myeloma is a fatal disease characterized by clonal proliferation of plasma cells in the bone marrow." | ( Anderson, KC; Blotta, S; Cervi, D; Cholujova, D; Daley, JF; Delmore, J; Hideshima, T; Jakubikova, J; Kim, K; Klippel, S; Leiba, M; McMillin, DW; Mitsiades, CS; Nahar, S; Negri, J; Ooi, M; Richardson, PG; Sedlak, J, 2011) |
| "Multiple myeloma is an incurable disease requiring the development of effective therapies which can be used clinically." | ( Blomhoff, HK; Blomhoff, R; Bogen, B; Follin-Arbelet, V; Hauglin, H; Hofgaard, PO; Naderi, S; Sundan, A, 2011) |
| "Multiple myeloma is a plasma cell malignancy that is heterogeneous with respect to its causative molecular abnormalities and the treatment response of patients." | ( Amiot, M; Avet-Loiseau, H; Bataille, R; Bodet, L; Descamps, G; Dousset, C; Gomez-Bougie, P; Le Gouill, S; Maïga, S; Moreau, P; Pellat-Deceunynck, C; Touzeau, C, 2011) |
| "Multiple myeloma is still an incurable hematological malignancy despite the development of high-dose chemotherapy with stem cell transplantation." | ( Kizaki, M; Sagawa, M; Tozawa, K, 2011) |
| "Patients with multiple myeloma are usually treated with IV bisphosphonates soon after diagnosis." | ( Hewson, ID, 2011) |
| "Multiple myeloma is largely an incurable malignant plasma cell neoplasm; however, the landscape of its treatment is rapidly changing." | ( Alsina, M; Nishihori, T, 2011) |
| "Multiple myeloma is a malignant neoplasm of plasma cells, for which there is no known cure." | ( Esteves, GV; Mariz, JM, 2012) |
| "Multiple myeloma is characterized by the accumulation of tumor plasma cells in the bone marrow." | ( Apcher, S; Arnulf, B; Bono, C; Bories, JC; Fermand, JP; Galicier, L; Harel, S; Karlin, L; Labaume, S; Mouly, E; Sauvageon, H, 2012) |
| "Newly diagnosed multiple myeloma is not included in this study." | ( Aziz, A; Baqui, MN; Begum, M; Debnath, RC; Dipta, TF; Habib, MA; Kabir, AL; Rahman, F; Rahman, MJ, 2012) |
| "Multiple myeloma is one of numerous malignancies characterized by increased glucose consumption, a phenomenon with significant prognostic implications in this disease." | ( Cheng, JC; Krett, NL; McBrayer, SK; Rosen, ST; Shanmugam, M; Singhal, S, 2012) |
| "Multiple myeloma is a hematopoietic cancer of the B-lineage, characterized by karyotypic instability, including chromosomal translocations involving the IGH locus and several translocation partners." | ( Belch, AR; Harizanova, J; Mai, S; Martin, LD; Pilarski, LM; Righolt, CH; Zhu, G, 2012) |
| "As multiple myeloma is an incurable disease that requires new therapeutic approaches, we investigated whether targeting the translation initiation pathway could be a target for myeloma therapy." | ( Amiot, M; Bouscary, D; Descamps, G; Gomez-Bougie, P; Green, A; Le Gouill, S; Maïga, S; Moreau, P; Pellat-Deceunynck, C; Tamburini, J, 2012) |
| "Multiple myeloma is the second most common hematological disease caused by clonal proliferation of B cells." | ( Adam, Z; Al-Sahmani, M; Antošová, L; Antošová, M; Buliková, A; Hájek, R; Kaisarová, B; Kissová, J; Penka, M; Trnavská, I, 2012) |
| "Multiple myeloma is characterized by an overproduction of malignant plasma cells in the bone marrow." | ( Kumar, N; Sharma, U; Singh, B; Singh, C, 2012) |
| "Multiple myeloma is an incurable malignant disorder of plasma cells in the bone marrow." | ( An, IS; An, S; Bae, S; Cha, HJ; Choi, YM; Jeong, HJ; Kim, K; Koh, HJ; Lee, SJ; Lim, DJ, 2012) |
| "Multiple myeloma is a common malignancy accounting for approximately 1% of all malignancies worldwide." | ( Bruce, JT; Devine, SM; Elder, P; Hofmeister, CC; Mastronarde, JG; Phillips, G; Tran, JM; Wood, KL, 2012) |
| "Multiple myeloma is an entity of cytogenetically and genetically heterogenous plasma cell neoplasms." | ( Chinen, Y; Horiike, S; Iida, S; Kiyota, M; Kobayashi, T; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagoshi, H; Nakayama, R; Ri, M; Sakamoto, N; Shimura, Y; Shiotsu, Y; Taniwaki, M; Yamamoto-Sugitani, M, 2012) |
| "Multiple myeloma is a monoclonal tumor of plasma cells, and its development is preceded by a premalignant tumor with which it shares genetic abnormalities, including universal dysregulation of the cyclin D/retinoblastoma (cyclin D/RB) pathway." | ( Bergsagel, PL; Kuehl, WM, 2012) |
| "Multiple myeloma is responsible for a wide variety of renal pathologies." | ( Buadi, FK; Cha, SS; Dispenzieri, A; Eirin, A; Fervenza, FC; Gertz, M; Hayman, SR; Herrmann, SM; Irazabal, MV; Kumar, S; Kyle, RA; Lacy, MQ; Leung, N; Nasr, SH; Rajkumar, SV; Ramirez-Alvarado, M; Sethi, S; Witzig, TE; Zeldenrust, SR, 2012) |
| "Multiple myeloma is a haematological malignancy characterized by the clonal proliferation of plasma cells." | ( Cózar-Castellano, I; Joumady, I; Perdomo, G; Sáez-Benito, A; Tirado-Vélez, JM, 2012) |
| "Multiple myeloma is a plasma cell cancer with poor survival, characterized by the clonal expansion of multiple myeloma cells (MMC), primarily in the bone marrow." | ( Goldschmidt, H; Hose, D; Klein, B; Leonard, W; Moreaux, J; Rème, T; Requirand, G; Veyrune, JL, 2012) |
| "The treatment of multiple myeloma is evolving rapidly." | ( Rajkumar, SV, 2012) |
| "Multiple myeloma is a malignant still incurable plasma cell disorder." | ( Camaschella, C; Campanella, A; Cenci, S; Fontana, F; Frenquelli, M; Marcatti, M; Santambrogio, P; Sitia, R; Tonon, G, 2013) |
| "Multiple myeloma is caused by the expansion of monoclonal plasma cells and secretion of M-protein (immunoglobulins, Bence Jones protein and free light chain)." | ( Suzuki, K, 2013) |
| "Abstract Multiple myeloma is a common hematological malignancy that urgently requires new approaches to treatment, since the disease is not curable using current chemotherapeutic regimens." | ( Conrad, DM; Coombs, MR; Doucette, CD; Hilchie, AL; Hoskin, DW; Liwski, RS; Zemlak, T, 2013) |
| "Multiple myeloma is divided into two distinct genetic subtypes based on chromosome content." | ( Bergsagel, PL; Chesi, M, 2013) |
| "Multiple myeloma is a plasma cell malignancy that leads to bone pain, pathological fracture, anaemia, renal failure and recurrent bacterial infections." | ( Basu, D; Dutta, TK; Sridhar, S, 2011) |
| "Multiple myeloma is the most common cause of primary malignancy in bones." | ( Agarwal, A; Chirindel, A; Shah, BA; Subramaniam, RM, 2013) |
| "Multiple myeloma is a hematologic malignancy characterized by the proliferation of neoplastic plasma cells in the bone marrow." | ( Baughn, LB; Deshpande, R; Dolloff, NG; Janz, S; Linden, MA; Mansoor, A; Myers, CL; Sarver, A; Stessman, HA; Sunderland, JJ; Van Ness, BG; Walsh, SA; Xia, T; Zhan, F, 2013) |
| "Multiple myeloma is the second most common hematologic malignancy." | ( Liu, Z; Zhang, G; Zhang, Z, 2013) |
| "Multiple myeloma is a malignancy of B cells characterized by accumulation of abnormal plasma cells in the bone marrow." | ( Belch, A; LeBlanc, R; Mezzi, K; Olujohungbe, A; Reece, D; Song, K; White, D; Zaman, F, 2013) |
| "Multiple myeloma is a clonal plasma cell disorder in which growth and proliferation are linked to a variety of growth factors, including insulin-like growth factor type I (IGF-I)." | ( Chettab, K; Dumontet, C; Herveau, S; Huber, AL; Jordheim, LP; Manié, S; Matera, EL; Tagoug, I, 2013) |
| "Outcome in multiple myeloma is highly variable and a better understanding of the factors that influence disease biology is essential to understand and predict behavior in individual patients." | ( Brioli, A; Davies, FE; Johnson, DC; Kaiser, MF; Melchor, L; Mirabella, F; Morgan, GJ; Walker, BA; Wardell, CP; Wu, P, 2013) |
| "Multiple myeloma is a non-curable B-cell malignancy in which iron metabolism plays an important role." | ( Daniels-Wells, TR; Lichtenstein, A; Penichet, M; VanderWall, K, 2013) |
| "Multiple myeloma is a malignant silent incurable plasma cell disorder." | ( Mehde, AA; Mehdi, WA; Zainulabdeen, JA, 2013) |
| "Multiple myeloma is a neoplasm of plasma cells that results in the overproduction of light and heavy chain monoclonal immunoglobulins." | ( El Azeeim, HA; El Husseiny, NM; Kasem, N; Mattar, MW, 2014) |
| "Multiple myeloma is one of the most common hematological malignancies with increasing prevalence." | ( Klánová, M; Špička, I, 2013) |
| "Multiple myeloma is a hematological cancer that is considered incurable despite advances in treatment strategy during the last decade." | ( Bachke, S; Bellacchio, E; Gilljam, KM; Holien, T; Misund, K; Müller, R; Otterlei, M; Rø, TB; Sundan, A; Våtsveen, TK, 2013) |
| "Multiple myeloma is a malignancy of plasma cells in the bone marrow." | ( Gras, J, 2013) |
| "Multiple myeloma is a lethal malignancy with an unknown etiology and no prevention strategy." | ( Birmann, BM; Colditz, GA; Giovannucci, EL; Rosner, BA, 2014) |
| "Multiple myeloma is a highly treatable but still incurable malignancy." | ( Cavallo, F; Cerrato, C; Mina, R; Palumbo, A, 2013) |
| "Multiple myeloma is a hematologic malignancy originating from clonal plasma cells." | ( Buck, AK; Einsele, H; Jörg, G; Knop, S; Lapa, C; Lückerath, K; Rosenwald, A; Samnick, S; Spahmann, A, 2013) |
| "Multiple myeloma is the second most common type of hematologic malignancy." | ( Ratliff, PD; Shely, RN, 2014) |
| "Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment." | ( Cavallo, F; Genadieva-Stavric, S; Palumbo, A, 2014) |
| "Multiple myeloma is the most frequent indication for high-dose melphalan (HDM) chemotherapy with autologous stem cell transplantation (ASCT)." | ( Brandt, SJ; Cai, Y; Freytes, CO; Giglia, JL; Hart, AJ; Holt, CC; Toro, JJ; White, MJ; Williams, SM, 2014) |
| "Multiple myeloma is a hematologic malignancy characterized by plasma cell clonal expansion as well as end-organ damage due to increased levels of monoclonal proteins in both the plasma and urine." | ( Chen, SE; Highsmith, KN; Horowitz, S, 2014) |
| "Multiple myeloma is a mostly incurable malignancy characterized by the expansion of a malignant plasma cell (PC) clone in the human bone marrow (BM)." | ( Atanackovic, D; Ben-Batalla, I; Binder, M; Bokemeyer, C; Cubas-Cordova, M; Fehse, B; Fiedler, W; Gensch, V; Hesse, E; Hose, D; Janning, M; Klein, B; Kröger, N; Loges, S; Meissner, T; Pantel, K; Raab, MS; Riecken, K; Sawall, S; Schewe, D; Seckinger, A; Taipaleenmaeki, H; Waizenegger, JS; Weinhold, N; Wroblewski, M, 2015) |
| "Multiple myeloma is an incurable often devastating disease that is responsible for 1-2% of all cancers." | ( Becker, PS; Bensinger, WI; Burwick, N; Green, DJ; Holmberg, L; Libby, EN, 2015) |
| "Multiple myeloma is a malignant proliferative disease of plasma cells in the bone marrow and remains largely incurable." | ( Adachi, K; Honma, Y; Ikejiri, F; Inoue, M; Jo, Y; Kawakami, K; Kumanomidou, S; Miyake, T; Moriyama, I; Okada, M; Onishi, C; Suzumiya, J; Takahashi, T; Takami, S; Tanaka, J, 2015) |
| "Multiple myeloma is a malignant disorder characterized by bone marrow proliferation of plasma cells and by overproduction of monoclonal immunoglobulin detectable in the sera (M-spike)." | ( Bergsagel, PL; Bertilaccio, MT; Bordini, J; Camaschella, C; Campanella, A; Chesi, M; Fermo, I; Ponzoni, M, 2015) |
| "Multiple myeloma is an incurable plasma cell cancer selectively localized in the bone marrow." | ( Aljawai, Y; Asara, JM; Ghobrial, IM; Huynh, D; Kimmelman, AC; Maiso, P; Mishima, Y; Moschetta, M; Roccaro, AM; Sacco, A, 2015) |
| "Multiple myeloma is a plasma cell malignancy with an estimated 26,850 new cases and 11,240 deaths in 2015 in the United States." | ( Boise, LH; Lonial, S; Shah, SP, 2015) |
| "Multiple myeloma is one of the most common haematological malignancies in the USA and is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS)." | ( Carlsson, NP; Carson, KR; Chang, SH; Colditz, GA; Luo, S; O'Brian, KK; Thomas, TS, 2015) |
| "Multiple myeloma is the second most frequent haematological disease." | ( Bladé, J; García-Sanz, R; Lahuerta, JJ; Martínez-López, J; Mateos, MV; Ocio, EM; Paiva, B; Rosiñol, L; San Miguel, JF, 2015) |
| "Extramedullary multiple myeloma is more often seen on FDG-PET/CT in the context of a hematogeneous/lymphangiogenic spread pattern and less commonly as a direct extension of osseous plasmacytomas." | ( Jacene, H; Munshi, NC; Ramaiya, NH; Sakellis, C; Shinagare, AB; Tirumani, SH; Van den Abbeele, AD, 2016) |
| "Multiple myeloma is the second most common hematological neoplasm that also affects young patients." | ( Bucalossi, A; Cioffi Squitieri, N; Guerrini, S; Mazzei, FG; Mazzei, MA; Volterrani, L, 2016) |
| "Multiple myeloma is a common hematological malignancy arising in the bone marrow." | ( Alberich-Bayarri, Á; Martí-Bonmatí, L; Ramirez-Fuentes, C; Ruiz-Llorca, C, 2015) |
| "Multiple myeloma is a common haematological malignancy and immune dysfunction is the hallmark of the disease." | ( Dadić-Hero, E; Dobrila-Dintinjana, R; Gačić, V; Ivandić, J; Načinović-Duletić, A; Petrov, B; Valković, T, 2015) |
| "Multiple myeloma is a plasma cell skeletal malignancy." | ( Hazlehurst, L; Lynch, CC; Shay, G, 2016) |
| "Multiple myeloma is still an incurable hematological malignancy of monoclonal B-lymphocytes." | ( Blaum-Feder, S; Schmeel, FC; Schmeel, LC; Schmidt-Wolf, IG, 2015) |
| "Multiple myeloma is a neoplastic plasma cell disorder that is characterized by clonal proliferation of plasma cells in the bone marrow, monoclonal protein in the blood and/or urine, and associated organ dysfunction and biomarkers." | ( Afifi, S; Azimi, M; Landgren, O; Lendvai, N; Michael, A; Rodriguez, M, 2015) |
| "Multiple myeloma is a malignant plasma cells dyscrasia that mainly affects patients older than 65 years." | ( Carrier, M; de Moreuil, C; Delluc, A; Eveillard, JR; Ianotto, JC, 2016) |
| "Multiple myeloma is a fatal plasma cell neoplasm accounting for over 10,000 deaths in the United States each year." | ( Brody, J; Chari, A; Cho, HJ; Divakar, SK; Jagannath, S; Jiang, Z; Kuo, PY; Leshchenko, VV; Parekh, S; Perumal, D; Reddy, EP; Reddy, MV; Zhang, W, 2016) |
| "Multiple myeloma is a disease of the elderly, with about a third of patients at diagnosis older than 75 years of age." | ( Ailawadhi, S; Gay, F; Larocca, A; Pawlyn, C; Roy, V, 2016) |
| "Multiple myeloma is a malignancy of plasma cells accounting for approximately 1% of cancers and 12% of haematological malignancies." | ( Coyne, I; Hayden, PJ; Scott, K; Wheatley, K; Will, A, 2016) |
| "Multiple myeloma is a malignant plasma cell dyscrasia that is becoming more prevalent in an increasingly ageing population." | ( Deighan, WI; Keren, DF; McNicholl, FP; O'Kane, MJ, 2016) |
| "Multiple myeloma is the most common primary malignant disease of bone marrow." | ( Nagy, Z, 2016) |
| "Multiple myeloma is an aggressive tumour able to suppress osteoblastogenesis probably mediated by bone marrow mesenchymal stromal cells (BM-MSCs) that can also support plasma cell growth/survival." | ( Alessandri, G; Benetti, A; Berenzi, A; Boniotti, J; Bonomi, A; Coccè, V; Mazzoleni, G; Pascucci, L; Pessina, A; Sordi, V; Steimberg, N, 2017) |
| "Multiple myeloma is an incurable B-cell malignancy with a natural history that involves alternating periods of remission and subsequent relapse." | ( Bloudek, L; Globe, D; Jagannath, S; Kish, JK; Kuriakose, ET; Orloski, L; Roy, A; Siegel, DS, 2016) |
| "Multiple myeloma is a clonal B-cell malignancy, characterised by proliferation of plasma cells and secretion of paraproteins." | ( Iqbal, N; Majid, H; Shaikh, MU; Tariq, MU, 2016) |
| "Multiple myeloma is an incurable complex disease characterized by clonal proliferation of malignant plasma cells in a hypoxic bone marrow environment." | ( Brede, G; Børset, M; Misund, K; Sponaas, AM; Sundan, A; Tian, E; Våtsveen, TK; Waage, A; Zhang, Q, 2016) |
| "Multiple myeloma is an incurable malignant plasma cell-originating cancer." | ( Lee, HS; Min, CK, 2016) |
| "Multiple myeloma is unique among cancers because proteasomal inhibition has good clinical effects." | ( Baranowska, K; Bjørkøy, G; Buene, G; Darvekar, S; Holien, T; Johansson, I; Misund, K; Starheim, KK; Sundan, A; Waage, A, 2016) |
| "Multiple myeloma is the second most common type of blood cancer and remains incurable despite advances in therapy." | ( Lipe, B; Mikhael, J; Vukas, R, 2016) |
| "Multiple myeloma is a malignant hematological disorder of the mature B-cell lymphocytes originating in the bone marrow." | ( Bier, G; Fritz, J; Horger, M; Ioanoviciu, SD; Kum, S; Schabel, C; Weisel, K, 2016) |
| "Multiple myeloma is a plasma cell malignant clone proliferation diseases and has been remained incurable." | ( An, R; Hou, J, 2016) |
| "Multiple myeloma is the second most prevalent hematologic malignancy and thought to be incurable." | ( Liu, W; Lu, W; Pan, J; Ruan, T; Tao, K; Wu, C; Yan, C; Zhang, C; Zhang, W; Zhu, X, 2018) |
| "Multiple myeloma is a neoplastic proliferation of monoclonal plasma cells." | ( Bettencourt, MJ; Capela, T; Russo, P; Tomé, AL, 2017) |
| "Multiple myeloma is a fetal form of plasma cell malignancy characterized by abnormal clonal proliferation of plasma cells." | ( Jung, JI; Kim, J; Kim, SA; Lee, Y; Park, KY, 2017) |
| "Multiple myeloma is a very heterogeneous disease with variable survival." | ( Alarcón-Payer, C; Cabeza Barrera, J; de la Guardia, AMDVD; García Collado, CG; Jiménez Morales, A; Jurado Chacón, M; Martín-García, A; Ríos-Tamayo, R; Sánchez-Rodríguez, D, 2017) |
| "Multiple myeloma is a haematological disease caused by proliferation of malignant plasma cells in bone marrow." | ( Canoz, O; Eser, B; Kaynar, L; Tiren, N; Yildizhan, E, 2017) |
| "Multiple myeloma is a fatal hematological malignancy with high rates of drug resistance and relapse." | ( Mager, DE; Nanavati, C; Ruszaj, D, 2017) |
| "Progression to multiple myeloma is the most common pattern of relapse." | ( Khosa, R; Nangia, S; Seth, S, 2017) |
| "Multiple Myeloma is a cancer of plasma cells associated with significantly reduced survival." | ( Boyd, KD; Houlston, RS; Kaiser, MF; Shah, V, 2017) |
| "Multiple myeloma is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS), which is usually only treated by a form of anti-multiple myeloma therapy if it is causing substantial disease through deposition of secreted M proteins." | ( Afzal, Z; Bunce, CM; Cairns, DA; Campbell, JP; Child, JA; Drayson, MT; Gregory, W; Heaney, JLJ; Jackson, GH; Kaiser, M; Morgan, GJ; Owen, R; Pandya, S, 2017) |
| "Multiple myeloma is a heterogeneous disease with a prognosis that varies with patient factors, disease burden, tumor biology, and treatments." | ( Barley, K; Barlogie, B; Chari, A; Cho, HJ; Jagannath, S; Lancman, G; Madduri, D; Moshier, E; Parekh, S; Tremblay, D, 2017) |
| "Multiple myeloma is the second most frequent hematological disease." | ( Mateos, MV; San Miguel, JF, 2017) |
| "Multiple myeloma is known as a constitutive NF-κB activating disease, and the proteasome inhibitor bortezomib is used to treat multiple myeloma and mantle cell lymphoma." | ( Hayashi, M; Imai, Y; Kido, K; Manabe, E; Sawasaki, T; Takahashi, H; Takeda, H; Uematsu, A, 2018) |
| "Multiple myeloma is characterised by monoclonal paraprotein production and osteolytic lesions, commonly leading to skeletal-related events (spinal cord compression, pathological fracture, or surgery or radiotherapy to affected bone)." | ( Cheng, P; Durie, B; García-Sanz, R; Krejčí, M; Laribi, K; Legieć, W; Raje, N; Roodman, GD; Shimizu, K; Terpos, E; Warner, D; Willenbacher, W; Zhu, L, 2018) |
| "Multiple myeloma is a hematologic disease with high mortality rates all over the world." | ( Barletta, PA; Salguero, DA; Sierraalta, W, 2018) |
| "Multiple myeloma is usually fatal due to serial relapses that become progressively refractory to therapy." | ( Ayers, EC; Carroll, MP; Cohen, AD; Das, R; Davis, MM; Dengel, K; Dhodapkar, K; Dhodapkar, MV; Garfall, AL; Hwang, WT; June, CH; Kerr, ND; Krevvata, M; Kulikovskaya, I; Lacey, SF; Lamontagne, A; Levine, BL; Mangan, PA; Matsui, WH; Maus, MV; Melenhorst, JJ; Milone, MC; Nunez-Cruz, S; Siegel, DL; Stadtmauer, EA; Vogl, DT; Wang, Q; Weiss, BM; Young, RM, 2018) |
| "Multiple myeloma is a hematologic malignancy that is unable to be cured and has significant impact throughout the world." | ( Vandross, A, 2017) |
| "Multiple myeloma is a hematologic malignancy affecting bone marrow derived plasma cells." | ( Aceituno, S; Appierto, M; Gozalbo, I; Lizán, L, 2018) |
| "Multiple myeloma is a cancer of malignant plasma cells which stimulates osteoclasts and is associated with increased bone turnover and osteolysis." | ( Kalin-Hajdu, E; Martin, TG; Narayan, R; Tan, M; Wong, SW, 2019) |
| "Multiple myeloma is a plasma cell neoplasm that has seen impressive improvements in outcomes in recent years with combination therapies, such as proteasome inhibitors and immunomodulatory drugs." | ( Arnall, JR; Harvey, RD; Moore, DC, 2019) |
| "Multiple myeloma is an incurable hematological malignancy that relies on drug combinations for first and secondary lines of treatment." | ( Chng, WJ; Chow, EK; Ho, CM; Ho, D; Hooi, L; Jha, S; Karnani, N; Rashid, MBMA; Silva, A; Tan, PF; Teh, AL; Toh, TB; Zhang, Y, 2018) |
| "Multiple myeloma is an uncommon haematological cancer of plasma cells." | ( Tomlinson, R, 2018) |
| "Multiple myeloma is a hematological disease; its prognosis is largely influenced by renal function." | ( Engelhardt, M; Grünewald, J; Ihorst, G; Kleber, M; Reinhardt, H; Schmidts, A; Terpos, E; Walz, G; Wäsch, R; Zschiedrich, S, 2019) |
| "Multiple myeloma is rare B cell malignancy that affects elderly." | ( Mahmood, SK; Niazi, SK; Noor, M; Sana, F, 2018) |
| "Multiple myeloma is a plasma cell malignancy, which develops in the bone marrow and frequently leads to severe bone destruction." | ( Chantry, AD; Down, JM; Evans, H; Green, AC; Lath, D; Lawson, MA; Paton-Hough, J; Snowden, JA; Tazzyman, S, 2019) |
| "Multiple myeloma is a very heterogeneous disease comprising a number of genetic entities that differ from each other in their evolution, mode of presentation, response to therapy, and prognosis." | ( Nohgawa, M; Oka, S; Ono, K, 2018) |
| "Multiple myeloma is associated with a significant risk of venous thromboembolism (VTE), causing substantial levels of morbidity and mortality." | ( Bradbury, C; Rocci, A; Swan, D; Thachil, J, 2018) |
| "Multiple myeloma is a hematological malignancy characterized by uncontrolled growth of plasma cells." | ( Deshantri, AK; Fens, MH; Groen, RWJ; Mandhane, SN; Martens, ACM; Metselaar, JM; Mutis, T; Ruiter, RWJ; Schiffelers, RM; Storm, G; van Bloois, L; Varela-Moreira, A, 2019) |
| "Multiple myeloma is a rare and incurable type of cancers." | ( Guojun, Z; Huihan, W; Rong, Z; Ying, Y; Yingchun, L; Zhuogang, L, 2019) |
| "Multiple myeloma is still an incurable disease but the recent therapeutics progress have revolutionized its management and improved prognosis." | ( Roussel, M; Royer, B; Talbot, A, 2018) |
| "Multiple myeloma is a malignancy of antibody-secreting plasma cells." | ( Auclair, D; Bahlis, NJ; Barwick, BG; Boise, LH; Dhodapkar, MV; Gupta, VA; Hofmeister, CC; Jaye, DL; Kaufman, JL; Keats, JJ; Lonial, S; Neri, P; Nooka, AK; Vertino, PM, 2019) |
| "Multiple myeloma is a malignancy of terminally differentiated plasma cells representing the second most common hematological malignancy." | ( Broski, SM; Glazebrook, KN; Kumar, S, 2019) |
| "Multiple myeloma is a fatal plasma cell malignancy that is reliant on the bone marrow microenvironment." | ( Clark, KC; Coulter, EA; Croucher, PI; Evdokiou, A; Hewett, DR; Mrozik, KM; Noll, JE; Opperman, KS; Psaltis, PJ; Schwarz, N; Vandyke, K; Zannettino, AC, 2019) |
| "Multiple myeloma is a monoclonal proliferation of plasma cells with common involvement of vertebrae, ribs and skull vault." | ( Abdelzaher, E; Badr-El-Dine, M; Eid, M; Elshennawy, R, 2020) |
| "Patients with multiple myeloma are generally older and vary in fitness levels, which may influence the clinical benefit of treatment." | ( Attal, M; Belch, A; Boyle, E; Chen, WM; Costa, B; Dimopoulos, MA; Facon, T; Guo, S; Houck, V; Hulin, C; Kim, K; Leleu, X; Lorraine Chretien, M; Ludwig, H; Macro, M; Manier, S; Meuleman, N; Mohty, M; Moreau, P; Renwick, W; Rodriguez-Otero, P; Rose, C; Silvia Monzini, M; Sturniolo, M; Tempescul, A; Tinel, A; Yves Mary, J; Zamagni, E, 2020) |
| "Multiple myeloma is a plasma cell malignancy that causes debilitating bone disease and fractures, in which TGFβ plays a central role." | ( Chantry, AD; Down, JM; Evans, HR; Green, AC; Hudson, K; Lath, D; Lawson, MA; Owen, R; Paton-Hough, J; Reilly, GC; Walkley, B, 2019) |
| "Multiple myeloma is the cancer of plasma cells." | ( Fujimaki, S; Fujiwara, M; Fujiwara, T; Fukuhara, N; Harigae, H; Ito, T; Iwaki, K; Onishi, Y; Ono, K; Saito, K; Sasaki, K; Suzuki, C; Tamura, H; Tanaka, T; Yokoyama, H, 2019) |
| "Multiple myeloma is an incurable, bone marrow-dwelling malignancy that disrupts bone homeostasis causing skeletal damage and pain." | ( Arezes, J; Armitage, AE; Ashley, N; Drakesmith, H; Edwards, CM; Edwards, JR; Frost, J; Gooding, S; Gray, N; Knowles, H; Lim, PJ; Martinez-Hackert, E; Mead, AJ; Morris, EV; Olechnowicz, SWZ; Pasricha, SR; Ramasamy, K; Repapi, E; Waugh, C, 2019) |
| "BACKGROUND Multiple myeloma is mainly a disease of the elderly." | ( Dung, PC; Man, HV, 2019) |
| "Multiple myeloma is a bone marrow-based hematological malignancy accounting for approximately two per cent of cancers." | ( Adams, A; Estcourt, LJ; Jakob, T; Kuhr, K; Langer, P; Monsef, I; Ocheni, S; Piechotta, V; Scheckel, B; Scheid, C; Skoetz, N; Theurich, S, 2019) |
| "Multiple myeloma is a plasma cell malignancy that thrives in the bone marrow (BM), with frequent progression to new local and distant bone sites." | ( Gowda, PS; Javed, A; Li, J; Lu, Y; Ponnazhagan, S; Trotter, TN; Xu, X; Yang, Y; Zhang, C, 2020) |
| "Multiple myeloma is an incurable and fatal cancer of immunoglobulin-secreting plasma cells." | ( Fedele, PL; Gong, JN; Gray, DHD; Grigoriadis, G; Harrison, SJ; Huang, DCS; Ko, ME; Low, MSY; Nolan, GP; Roberts, AW; Segal, D; Strasser, A; Tan, T; Teh, CE; Vandenberg, CJ, 2020) |
| "Multiple myeloma is a malignant neoplasm of plasma cells." | ( Altuntaş, F; Batgi, H; Dal, MS; Kızıl Çakar, M; Merdin, A; Yiğenoğlu, TN, 2020) |
| "BACKGROUND Multiple myeloma is featured by the proliferation of malignant plasma cell in bone marrow." | ( Hao, C; Li, J; Pei, X; Wang, L; Zhang, R; Zhang, Z, 2020) |
| "Multiple myeloma is an incurable progressive neoplastic disease that accounts for 10% of all hematologic malignancies." | ( Kassir, N; Li, Y; Palmisano, M; Wang, X; Zhou, S, 2020) |
| "Treatment of multiple myeloma is not curative, but targeting CD38 improves patient survival." | ( Agis, H; Blank, A; Blau, IW; Chatterjee, M; Einsele, H; Engelhardt, M; Ferstl, B; Goldschmidt, H; Griese, J; Härtle, S; Jarutat, T; Peschel, C; Raab, MS; Röllig, C; Schub, N; Weirather, J; Weisel, K; Winderlich, M, 2020) |
| "Multiple myeloma is an incurable haematological malignancy, representing over 10% of haematological cancers in the USA." | ( Anderson, K; Bringhen, S; Byrne, C; Chauhan, D; Harmenberg, J; Mellqvist, UH; Nordström, E; Paba-Prada, C; Palumbo, A; Plesner, T; Reeves, B; Richardson, PG; Sonneveld, P; Voorhees, P; Zubair, H, 2020) |
| "Multiple myeloma is a blood cell cancer and can cause symptoms such as bone loss and fatigue." | ( John, T; Ma, H; Park, J; Rayalam, S; Rogers, LJ; Tucker, M; Wang, X; Wu, Y, 2020) |
| "Multiple myeloma is a plasma cell malignancy that escapes from apoptosis by heterogeneously over-expressing anti-apoptotic BCL2 proteins." | ( Amiot, M; Bellanger, C; Descamps, G; Gomez-Bougie, P; Kervoëlen, C; Maiga, S; Maillet, L; Moreau, P; Pellat-Deceunynck, C; Seiller, C; Touzeau, C, 2020) |
| "Multiple myeloma is a hematologic cancer that disrupts normal bone marrow function and has multiple lines of therapeutic options, but is incurable as patients ultimately relapse." | ( Breen, S; Chen, R; Dimasi, N; Fleming, R; Hurt, EM; Iverson, WO; Karanth, S; Muniz-Medina, V; Novick, S; O'Day, T; Osbourn, J; Overstreet, MG; Rajan, S; Sadowska, A; Shah, DP; Thomas, SB; Tiberghien, AC; Walker, J; Ward, C; Wu, Y; Zheng, B, 2020) |
| "Multiple myeloma is a hematologic malignancy that predominantly affects older adults, with a median age at diagnosis of 70 years old." | ( Schoenbeck, KL; Wildes, TM, 2020) |
| "The progression of multiple myeloma is accompanied by complex cytogenetic and epigenetic alterations that include mutation or functional inactivation of tumor suppressor proteins and overexpression of oncoproteins." | ( Jagannath, S; Richard, S; Richter, J, 2020) |
| "Multiple myeloma is a plasma cell tumour with approximately 5500 new cases in the UK each year." | ( Auner, HW; Bailey, L; Brown, S; Brudenell Straw, F; Cook, G; Cook, M; Dawkins, B; Flanagan, L; Hinsley, S; Kaiser, MF; McKee, S; Meads, D; Reed, S; Sherratt, D; Walker, K, 2020) |
| "Although multiple myeloma is a low-risk disease for developing tumor lysis syndrome (TLS), treatment with these novel therapies might increase TLS risk." | ( Hotta, Y; Iida, S; Kimura, K; Komatsu, H; Kondo, M; Sanagawa, A; Yamauchi, K, 2020) |
| "Multiple myeloma is the second most common blood cancer in New Zealand with higher incidence in Māori and Pacific Island populations." | ( Baker, B; Chan, H; Chien, N; Goodman, H; Romeril, K, 2020) |
| "Symptomatic multiple myeloma is commonly complicated by acute kidney injury through various mechanisms." | ( Belmouaz, M; Bridoux, F; Fermand, JP; Leung, N; Nasr, SH; Ronco, P; Royal, V, 2021) |
| "Multiple myeloma is a plasma cell dyscrasia accounting for 1% of neoplastic diseases and is the second most common hematologic malignancy after lymphoma." | ( Andrizzi, C; Campagna, S; Caravita di Toritto, T; Rago, A; Siniscalchi, A; Tordi, A, 2021) |
| "Progression of multiple myeloma is regulated by factors intrinsic to the clonal plasma cells (PC) and by the immune effector cells in the tumor microenvironment." | ( Kim, BS; Kim, TW; Lee, SE; Lim, JY; Min, CK; Park, SS; Ryu, DB, 2021) |
| "Multiple myeloma is an incurable hematological malignancy that impacts tens of thousands of people every year in the United States." | ( Alugubelli, RR; De Avila, G; Eschrich, SA; Fang, B; Garrett, TJ; Guingab-Cagmat, JD; Hampton, OA; Jiang, Z; Koomen, DC; Koomen, JM; Liu, M; Magaletti, DM; Meads, MB; Meke, LE; Nishihori, T; Oliveira, PS; Shain, KH; Silva, AS; Tungesvik, A; Welsh, EA, 2021) |
| "The prevalence of multiple myeloma is increasing and there is a need to evaluate escalating therapy costs (Canadian Cancer Statistics A, 2020)." | ( Bhella, S; Castonguay, V; Chen, BE; Cheung, MC; Dudebout, J; Gul, E; Hay, AE; Kukreti, V; Lalancette, M; Monteith, BE; Pater, J; Phua, C; Reece, D; Richardson, H; Shepherd, L; Sherry, M; Tiedemann, R; Venner, CP; Yen, H, 2021) |
| "Multiple myeloma is an incurable hematological malignancy." | ( Abousamra, N; Atia, DM; Eissa, M; El-Kott, AF; ElMenshawy, N; Farag, NA; Fawzi, E; Ghazi, H; Shahin, D, 2021) |
| "Multiple myeloma is a frequent hematologic malignancy." | ( Huang, Z; Li, H; Liu, D; Peng, S; Tan, H; Wang, Y, 2022) |
| "Multiple myeloma is characterized by a neoplastic proliferation of plasma cells primarily in the bone marrow." | ( Kanri, Y; Kobayashi, E; Minami, Y; Ogawa, R; Ogura, I; Okada, Y; Ono, J; Tanaka, A, 2022) |
| "Non-secretory multiple myeloma is a rare form of the disease that presents a diagnostic challenge." | ( Amaro, T; Martins, J; Pinto, J; Silva, M, 2021) |
| "Multiple myeloma is a genetically heterogeneous cancer of the bone marrow plasma cells (PC)." | ( Alvarez-Benayas, J; Atta, M; Auner, HW; Bua, M; Caputo, VS; Chaidos, A; Hatjiharissi, E; Karadimitris, A; Katsarou, A; May, PC; Papaioannou, M; Ponnusamy, K; Roberts, IAG; Sudbery, IM; Trasanidis, N; Xiao, X, 2021) |
| "Multiple myeloma is a cancer of plasma cells that often leads to complications including osteolytic bone lesions, nephropathy and neuropathy." | ( Barney, T; Jayaraman, AL; Lim, VM, 2021) |
| "Multiple myeloma is preceded by the early stages: monoclonal gammopathy of unknown significance (M." | ( Kunacheewa, C; Manasanch, EE, 2021) |
| "Multiple myeloma is known to be associated with neurological symptoms such as peripheral neuropathy, myelopathy, and radiculopathy; however, central nervous system involvement in multiple myeloma is uncommon." | ( Aratake, Y; Shindo, K; Takaya, R, 2021) |
| "Multiple Myeloma is a clonal proliferation of plasma cells with bone marrow as the primary site of occurrence." | ( Ali, MU; Bano, K; Malik, M; Maqsood, S, 2021) |
| "Multiple myeloma is a so far incurable malignant plasma cell disorder." | ( Bokemeyer, C; Ghandili, S; Leypoldt, LB; Weisel, KC, 2021) |
| "Multiple myeloma is a plasma cell malignancy that thrives in the bone marrow (BM)." | ( Gowda, PS; Javed, A; Li, J; Lu, Y; Murphy-Ullrich, JE; Suto, MJ; Trotter, TN; Xu, X; Yang, Y; Zhang, C, 2022) |
| "Multiple myeloma is currently incurable, and the incidence rate is increasing year by year worldwide." | ( Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y, 2022) |
| "Multiple myeloma is a plasma cell malignancy, accounting for approximately 1% of new cancer cases." | ( Aziz, A; Cui, Y; Dai, C; Gong, F; Hu, L; Li, R; Li, Z; Liang, L; Liu, J; Liu, X; Luo, S; Peng, H; Wang, H; Wang, Y; Xiang, R; Xiao, L; Xiao, X; Yi, H; Yuan, L; Zhou, H; Zhu, L; Zhu, Y, 2022) |
| "Multiple myeloma is an incurable, genetically heterogeneous disease, without available tailored therapeutic approaches." | ( Benson, D; Cocucci, E; Cottini, F; Guo, L; Hughes, T; Liu, B; Lozanski, G; Rodriguez, J; Sharma, N; Yang, Y, 2022) |
| "Multiple myeloma is still an incurable disease In the past decade, with the continuous progress of treatment methods, the progression-free survival of patients has been prolonged, but some patients still progress in the early stage of the disease." | ( Sun, Z; Wang, Z; Wei, H; Ye, X; Ye, Y; Yu, J, 2022) |
| "Multiple myeloma is a bone marrow cancer, which predominantly affects older people." | ( Best, P; Bird, J; Bowcock, S; Boyd, K; Cairns, DA; Cook, G; Coulson, AB; Dawkins, B; de Tute, R; Drayson, M; Gardner, H; Henderson, R; Hockaday, A; Jackson, G; Jenner, M; Jones, J; Kaiser, M; Kishore, B; Meads, D; Olivier, C; Owen, R; Parrish, C; Pawlyn, C; Rabin, N; Royle, KL, 2022) |
| "Patients with multiple myeloma are at increased risk of vascular thromboembolic events (VTEs)." | ( Anderson, LD; Baljevic, M; Bartlett, JB; Chari, A; Cortoos, A; Costa, LJ; Efebera, YA; Holstein, SA; Kaufman, JL; Laubach, J; Lin, TS; Patel, S; Pei, H; Reeves, B; Richardson, PG; Rodriguez, C; Sborov, DW; Shah, N; Silbermann, R; Vermeulen, J; Voorhees, PM, 2022) |
| "Multiple myeloma is a clonal disorder of malignant plasma cells that comprises approximately 10% of hematologic malignancies." | ( Huang, J; Liu, Q; Wei, M; Wu, F; Xie, C; Yang, F, 2022) |
| "Multiple myeloma is a plasma cell malignancy that is still largely incurable, despite considerable progress in recent years." | ( Bariana, M; Cassella, E; Colorado, I; Feinman, R; Heller, C; Heller, G; Liou, HC; Makhdoom, A; Mondello, P; Ouk, S; Rateshwar, J; Siegel, DS; Tuckett, A; Zakrzewski, JL, 2022) |
| "Multiple myeloma is a malignancy of plasma cells with around 6000 new cases per year in the UK." | ( Auner, HW; Boyd, K; Brown, S; Garg, M; Hall, A; Kaiser, M; Kendall, J; Roberts, S, 2022) |
| "Multiple myeloma is a haematological malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow." | ( Håland, E; Moen, IN; Starheim, KK; Vandsemb, EN, 2022) |
| "Multiple myeloma is a haematological malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow." | ( Håland, E; Moen, IN; Starheim, KK; Vandsemb, EN, 2022) |
| "Multiple myeloma is a haematological malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow." | ( Håland, E; Moen, IN; Starheim, KK; Vandsemb, EN, 2022) |
| "Multiple myeloma is one of the most common hematological malignancies worldwide." | ( Balcerczak, E; Jeleń, A; Michalska, K; Pietrzak, J; Saed, L; Żebrowska-Nawrocka, M, 2023) |
| "Multiple myeloma is one of the most common hematological malignancies worldwide." | ( Balcerczak, E; Jeleń, A; Michalska, K; Pietrzak, J; Saed, L; Żebrowska-Nawrocka, M, 2023) |
| "Multiple myeloma is a hematologic malignancy of plasma cells that manifests with bone marrow tumors causing lytic bone lesions." | ( Bergsagel, PL; Meermeier, EW, 2023) |
| "Multiple myeloma is characterized by clonal proliferation of plasma cells that accumulate preferentially in the bone marrow (BM)." | ( Bernabei, L; Bonner, EE; Cruz, Z; Eriksson, H; Gabrilovich, DI; Garcia-Gerique, L; Lawler, M; Lin, C; Liu, Q; Mastio, J; Muthumani, K; Nefedova, Y; Poncz, M; Rosenwasser, M; Törngren, M; Vogl, DT; Vogl, T, 2023) |
| "Multiple myeloma is a hematological neoplasm derived from plasma cells invariably developing in the bone marrow (BM)." | ( Baert, L; Barbon, PV; Bogen, B; Chavarria, O; Clement, E; Huard, B; Manfroi, B; McKee, T; Moreaux, J; Quintero, M; Sturm, N; Tveita, A; Van Kuppevelt, T; Zeller, A, 2023) |
| "Multiple myeloma is a hematological cancer characterized by relapse after treatment and poor prognosis." | ( Ballestrero, A; Calabrese, M; Ceccardi, A; Cuccarolo, P; Dameri, M; Garlaschi, A; Gristina, L; Stabile, M; Tagliafico, A; Valente, I; Zoppoli, G, 2023) |
| "Multiple myeloma is one of the most common hematologic malignancies, with approximately 400 patients diagnosed in Hungary annually." | ( Gaál, L; Masszi, T; Ruff, E; Syoreni, S; Szita, VR; Tóth, A; Varga, G; Wiedemann, Á, 2023) |
| "Although multiple myeloma is still incurable, an abundance of novel treatments have become available for relapsed and or refractory multiple myeloma (RRMM)." | ( Chen, H; Xu, W; Xu, Y; Yu, J; Zhou, F; Zhou, Y, 2023) |
| "Multiple myeloma is a highly heterogenous plasma cell malignancy, commonly seen in older patients." | ( An, G; Deng, S; Du, C; Fan, H; Hao, M; Li, C; Li, L; Liu, J; Mao, X; Qiu, L; Sui, W; Xu, Y; Yi, S; Zhao, J; Zhao, Y; Zou, D, 2023) |
| "What is the context?Multiple myeloma is associated with increased risk of thrombosis, although the potential role of platelets in this has not been evaluated." | ( Bye, AP; Gibbins, JM; Grech, H; Khan, D; Kriek, N; Laffan, M; Mitchell, JL; Ramasamy, K; Rana, RH; Sage, T; Shapiro, S; Thakurta, A; Unsworth, AJ, 2023) |
| Excerpt | Reference |
|---|
| "Further trials of rHuEpo in the treatment of multiple myeloma with and without renal failure are warranted." | ( Holley, JL; Nolan, TA; Piraino, B, 1992) |
| "277 untreated multiple myeloma patients of stage 1 (n = 33), II (n = 106) and III (n = 138) entered the study." | ( Bartels, H; Bartl, R; Braun, HJ; Coldewey, R; Deicher, H; Fischer, JT; Gramatzki, M; Leo, R; Peest, D; von Broen, IM, 1990) |
| "Glucocorticoids are widely used for the treatment of multiple myeloma." | ( Gomi, M; Katagiri, S; Kurata, Y; Moriwaki, K; Thompson, EB, 1990) |
| "A 69-year-old male, under active treatment for multiple myeloma, fractured his left maxillary second premolar palatal abutment tooth and requested treatment because his upper partial denture no longer fit." | ( Sager, RD; Theis, RM, 1990) |
| "136 untreated multiple myeloma patients of stage II and III were collected in the study." | ( Cammerer, U; Coldewey, R; Deicher, H; Hein, R; Hoffmann, L; Konyar, H; Kreuser, ED; Peest, D; Selbach, J; von Broen, IM, 1990) |
| "There have been major advances in the treatment of multiple myeloma in the past 20 years, but for the individual patient the prognosis still remains uncertain." | ( Dawidowich, J; Duczyminer-Kahana, M; Gelernter, I; Lurie, H; Meyerson, E; Pick, AI; Tamir, R; Vana, D; Weiss, H, 1990) |
| "50 patients were treated for multiple myeloma with 5-drug combination chemotherapy between Jan 1979 and Feb 1980." | ( , 1989) |
| "Seventy-five patients with previously untreated multiple myeloma were randomly treated with the association of Peptichemio, Vincristine and prednisone (PTC-VCR-P) or of melphalan and P (MPH-P) for first induction therapy." | ( Ascari, E; Cassano, E; Danova, M; Merlini, G; Montecucco, C; Riccardi, A; Ucci, G, 1986) |
| "The effects of the treatment of multiple myeloma (MM) with APD-bisphosphonate on bone destruction, the dissemination pattern of the MM, and toxicity for normal and malignant cells were investigated in an animal model, the 5T2 MM." | ( Bijvoet, OL; Brondijk, RJ; Croese, JW; Haaijman, JJ; Kazil, M; Radl, J; Reitsma, PH; van den Enden-Vieveen, MH; Zurcher, C, 1985) |
| "To evaluate possible synergism in the treatment of human multiple myeloma (MM), 23 evaluable patients who had relapsed with standard treatment were treated with cisplatin, BCNU, CTX, and prednisone." | ( Broun, GO; Cohen, HJ; Hiramoto, RN; Petruska, PJ, 1982) |
| "Interferon (IFN) treatment trials in multiple myeloma have yielded discordant results regarding response rates, maintenance duration, and survival times." | ( Cohen, AM; Eckhardt, S; Günczler, P; Huber, H; Ludwig, H; Morant, R; Nachbaur, D; Polliack, A; Seewann, HL; Senn, HJ, 1995) |
| "406 untreated multiple myeloma patients of stage I (n = 54), II (n = 148) and III (n = 204) were enrolled in the trial." | ( Bartels, H; Bartl, R; Braun, HJ; Coldewey, R; Deicher, H; Fett, W; Fischer, JT; Göbel, B; Leo, R; Peest, D, 1995) |
| "Prednisone is an active drug in the treatment of multiple myeloma." | ( Beckford, J; Bonnet, JD; Chilton, D; Gupta, V; Pierce, HI; Salmon, SE; Stock-Novack, D; Thompson, EB, 1994) |
| "Twenty-one previously untreated multiple myeloma (MM) patients and 10 previously treated patients with refractory or relapsed disease received two or three cycles of intermediate-dose melphalan (70 mg/m2) (IDM), administered intravenously every 6 weeks." | ( Dekker, AW; Lokhorst, HM; Meuwissen, OJ; Sonneveld, P; van der Griend, R; van Marwijk Kooy, M; van Oers, RH; Wijermans, PW, 1996) |
| "Thirty-seven patients with previously treated multiple myeloma (MM) underwent peripheral blood progenitor cell (PBPC) collection following high-dose cyclophosphamide and GM-CSF or sequential IL-3 and GM-CSF." | ( Crump, RM; Girouard, C; Imrie, K; Keating, A; Meharchand, J; Prince, HM; Stewart, AK; Sutherland, DR; Trip, K, 1996) |
| "Cytostatic treatment of multiple myeloma in combination with repetitive i." | ( Frickhofen, N; Friedrich, JM; Hoffmeister, A; Mattfeldt, T; Merkle, E; Prümmer, O; Weber, CK, 1996) |
| "Fifty-eight patients with previously untreated multiple myeloma were entered." | ( Gregory, SA; Greipp, PR; Kay, NE; Kyle, RA; O'Connell M, J; Oken, MM; Spiegel R, J; Tsiatis, A, 1996) |
| "Thus, the efficacy of ATRA for the treatment of human multiple myeloma remains to be ascertained." | ( Brouet, JC; Chopin, M; Labaume, S; Pla, M, 1998) |
| "Eighteen patients with previously untreated multiple myeloma were enrolled." | ( Gertz, MA; Greipp, PR; Khandekar, JD; Kyle, RA; Leong, T; Miller, HJ, 1998) |
| "This is a general overview on the treatment of multiple myeloma (MM) with particular emphasis on controversial aspects." | ( Bladé, J, 1999) |
| "Addition of bisphosphonates to standard treatment of multiple myeloma (MM) decreases bone pain and skeletal events without influencing bone healing." | ( Holbert, JM; Imseis, RE; Leventhal, MR; Palmieri, GM; Sebes, JI, 1999) |
| "Ten patients with previously untreated multiple myeloma entered the study." | ( Hassan, M; Lundin, J; Nilsson, C; Olsson, H; Osterborg, A, 1999) |
| "The established treatment for multiple myeloma (MM) comprises induction with infusional chemotherapy, high dose chemotherapy (HDC) and autologous transplantation followed by maintenance interferon." | ( Kulkarni, S; Mainwaring, PN; Powles, RL; Raje, N; Ramiah, V; Sumpter, K; Treleaven, J, 1999) |
| "The main form of cytotoxic treatment for multiple myeloma (MM) is conventional dose chemotherapy at present." | ( Araki, K; Fukuda, H; Hanada, S; Hirano, M; Ichimaru, M; Inaba, S; Konishi, H; Mikuni, C; Miura, A; Niimi, M; Ohno, Y; Sai, T; Shimamoto, Y; Shimoyama, M; Shirakawa, S; Tajima, K; Takenaka, T; Toki, H, 1999) |
| "13 patients with treatment-resistant multiple myeloma with advanced osteolytic lesions received combined pamidronate and thalidomide therapy." | ( Baran, W; Ciepłuch, H; Hellmann, A, 2002) |
| "Since the efficacy of L-OHP in the treatment of multiple myeloma (MM) has not yet been evaluated, we studied the antiproliferative activity of this compound in vitro in a panel of MM cell lines (XG1, XG1a, U266 and IM-9)." | ( Bonelli, P; Galea, E; Martelli, ML; Palmieri, C; Tagliaferri, P; Tassone, P; Tuccillo, F; Turco, MC; Venuta, S, 2002) |
| "A 61-year-old woman had been treated for multiple myeloma for 4 years when she developed abdominal pain." | ( Fukumitsu, H; Hoshikawa, T; Ishikawa, K; Makuuchi, H; Nasu, S; Sadahiro, S; Shibuya, M; Shimakura, Y; Suzuki, T; Tajima, T; Yasuda, S; Yazawa, N, 2001) |
| "Future progress in treating multiple myeloma NRC depends on better identification of new therapeutic targets that control progression from the stable asymptomatic to the progressive symptomatic phase of multiple myeloma." | ( Greipp, PR, 2000) |
| "Therefore, it can be used to treat untreated multiple myeloma patients." | ( Hong, WD; Huang, JQ; Li, J; Luo, SK, 2002) |
| "Twenty-one patients with untreated multiple myeloma were evaluated." | ( Nagai, M; Nishiyama, Y; Ohkawa, M; Satoh, K; Yamamoto, Y, 2003) |
| "Current treatment in multiple myeloma consists of three courses of chemotherapy in low doses with subsequent hematopoietic stem cell mobilization to the peripheral blood using high-dose cyclophosphamide, collection and conditioning with high-dose chemotherapy (melphalan) followed by retransplantation of autologous peripheral blood stem cells (PBSCT)." | ( Awedan, A; Blajer, B; Król, M; Rokicka, M; Torosian, T; Urbanowska, E; Wiktor-Jedrzejczak, W, 2003) |
| "We conducted a randomized trial of the treatment of multiple myeloma with high-dose chemotherapy followed by either one or two successive autologous stem-cell transplantations." | ( Attal, M; Bataille, R; Bouabdallah, R; Caillot, D; Doyen, C; Facon, T; Fuzibet, JG; Grosbois, B; Guilhot, F; Harousseau, JL; Hulin, C; Monconduit, M; Sotto, JJ; Voillat, L, 2003) |
| "The effect of in vivo drug treatments on multiple myeloma cell growth was monitored by serial determinations of serum levels of soluble IL-6 receptor (shuIL-6R), which is released by INA-6 cells and served as a marker of tumor growth." | ( Anderson, KC; Burger, R; Catley, L; Chauhan, D; Gozzini, A; Masciari, S; Munshi, NC; Neri, P; Podar, K; Savino, R; Shammas, M; Tagliaferri, P; Tassone, P; Venuta, S, 2005) |
| "Alkylating agents are often used to treat patients with multiple myeloma (MM)." | ( Aiba, A; Aizawa, Y; Aoki, S; Momoi, A; Nikkuni, K; Tsukada, N; Yagisawa, K, 2005) |
| "Several advances have been made in the treatment of multiple myeloma over the past decade, especially the arrival of new, active agents such as thalidomide (Thalomid), bortezomib (Velcade), and lenalidomide (Revlimid)." | ( Rajkumar, SV, 2005) |
| "(1) First-line treatment of multiple myeloma depends first and foremost on the patient's age." | ( , 2005) |
| "It is an effective treatment for multiple myeloma at disease recurrence and at diagnosis, both as a single agent and in combination with steroids or chemotherapy." | ( Bertola, A; Boccadoro, M; Callea, V; Cangialosi, C; Caravita, T; Falco, P; Grasso, M; Musto, P; Nunzi, M; Palumbo, A, 2005) |
| "Although the treatment of multiple myeloma has improved over the past decade, the disease remains incurable." | ( Bladé, J; Cibeira, MT; Rosiñol, L, 2005) |
| "Thalidomide is effective in the treatment of multiple myeloma." | ( Bartlett, JB; Stirling, D; Tozer, A; Zeldis, JB, 2005) |
| "Therefore, a challenge for treating multiple myeloma is discovering drugs targeting not only myeloma cells but also osteoclasts and osteoblasts." | ( Abdallah, BM; Andersen, TL; Boissy, P; Delaissé, JM; Kassem, M; Plesner, T, 2005) |
| "To evaluate lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome (MDS)." | ( Hammond, JM; Maier, SK, 2006) |
| "There is no evidence that early treatment of multiple myeloma is advantageous." | ( Kyle, RA; Vincent Rajkumar, S, 2006) |
| "FDA) for the treatment of multiple myeloma (MM) progressing after at least one prior therapy." | ( Farrell, AT; Kane, RC; Pazdur, R; Sridhara, R, 2006) |
| "A major limitation to the treatment of multiple myeloma by the thalidomide analogue CC-4047 (Actimid) is the development of a severe neutropenia." | ( Brown, KA; Macey, MG; McCarthy, DA; Schey, SA; Streetly, M, 2006) |
| "Despite advances in the treatment of multiple myeloma, it remains an incurable disease because of primary and secondary drug resistance." | ( Baumann, P; Emmerich, B; Meinhardt, G; Schmidmaier, R; Simsek, M, 2006) |
| "Recent advances in the treatment of multiple myeloma include bortezomib and thalidomide." | ( Anderson, KC; Hideshima, T; Mitsiades, C; Richardson, PG, 2006) |
| "The reasons for bisphosphonate treatment were multiple myeloma in 12 patients, breast cancer with bone metastasis in four patients and histiocytosis X in one patient." | ( Baumann, A; Czerny, C; Eisenmenger, G; Ewers, R; Hoffmann, M; Moser, D; Pietschmann, P; Wutzl, A, 2006) |
| "Thalidomide was introduced in the treatment of multiple myeloma in the late 1990s." | ( Harousseau, JL, 2006) |
| "Although treatable, multiple myeloma remains incurable in virtually all cases, with a median survival of 3-4 years." | ( Kenealy, M; Prince, HM, 2006) |
| "The use of arsenic compounds in the treatment of multiple myeloma (MM) is supported by the proposed mechanisms of action underlying the antitumor activity of arsenic and by preclinical studies showing antiproliferative and cytotoxic activities in cell culture and animal models." | ( Berenson, JR; Yeh, HS, 2006) |
| "Despite advances in the first-line treatment of multiple myeloma, almost all patients eventually relapse, become chemoresistant, and die of the disease." | ( Anderson, KC; Hideshima, T; Mitsiades, C; Richardson, PG, 2007) |
| "Patients with previously treated or untreated multiple myeloma were eligible." | ( Bahlis, N; Batts, ED; Fu, P; Gerson, SL; Kane, D; Liu, L; Maisel, C; O'Brien, T; Remick, S, 2007) |
| "Thalidomide is highly efficient in the treatment of multiple myeloma." | ( Maisnar, V; Radocha, J, 2007) |
| "It has been recently approved for the treatment of multiple myeloma, an incurable plasma cell tumour that accounts for 10-15% of all haematologic malignancies and for approximately 20% of deaths." | ( Brugnatelli, S; Brunetti, L; Corazza, GR; Gobbi, PG; Palladini, G; Perfetti, V; Sgarella, A, 2007) |
| "Melphalan is widely used in the treatment of multiple myeloma." | ( Brockmöller, J; Heider, U; Hohloch, K; Kaiser, R; Kühne, A; Muhlke, S; Niere, W; Overbeck, T; Schirmer, M; Sezer, O; Trümper, L, 2007) |
| "Bortezomib is active in heavily pretreated multiple myeloma patients; the dose-limiting toxicity is peripheral neuropathy (PN)." | ( Akpek, G; Badros, A; Can, I; Dalal, JS; Fenton, RG; Goloubeva, O; Heyman, M; Rapoport, AP; Thompson, J, 2007) |
| "Thalidomide is successfully used in the treatment of multiple myeloma, leprosy and various autoimmune diseases due to its anti-angiogenic, immunomodulatory and anti-inflammatory effects." | ( Alpay, N; Ayer, M; Küçükkaya, RD; Mete, O; Nalçaci, M; Yavuz, AS; Yenerel, MN; Yildirim, ND, 2007) |
| "Ninety four patients with previously untreated multiple myeloma were treated with a conventional chemotherapy program: cyclophosphamide, vincristine, melphalan, and prednisone (CVMP) and were randomized to received either zoledronic acid (4 mg, iv, every 28 d) or not (control group)." | ( Avilés, A; Castañeda, C; Cleto, S; Huerta-Guzmán, J; Nambo, MJ; Neri, N, 2007) |
| "Bortezomib, an approved agent for the treatment of multiple myeloma patients who have received at least one prior therapy, is also being investigated in the frontline setting." | ( Cavenagh, JD; Oakervee, H; Popat, R, 2007) |
| "Despite high dose treatment regimes multiple myeloma (MM) disease is still not curable." | ( Armann, J; Baumann, P; Grün, G; Mandl-Weber, S; Oduncu, F; Schmidmaier, R, 2008) |
| "For many years the treatment of multiple myeloma was limited to such regimens as melphalan-prednisone, high-dose dexamethasone, and vincristine-doxorubicin-dexamethasone (VAD)." | ( Richards, TA; Thomas, SK; Weber, DM, 2007) |
| "It is currently approved for the treatment of multiple myeloma patients who have received at least one prior therapy and who have already undergone or are unsuitable for transplantation." | ( Cavenagh, JD; Davies, FE; Jackson, GH; Morgan, GJ, 2008) |
| "The use of arsenic trioxide (ATO) to treat multiple myeloma (MM) is supported by preclinical studies as well as several phase 2 studies, but the precise mechanism(s) of action of ATO has not been completely elucidated." | ( Boise, LH; Gutman, D; Lee, KP; Morales, AA, 2008) |
| "Despite recent progress in its treatment, multiple myeloma (MM) remains incurable, thus necessitating identification of novel anti-MM agents." | ( Anderson, KC; Aviles, P; Chauhan, D; Faircloth, G; Gajate, C; Garayoa, M; Hideshima, T; Maiso, P; Mateos, MV; McMullan, CJ; Mitsiades, CS; Mitsiades, N; Mollinedo, F; Montero, JC; Munshi, NC; Ocio, EM; Otero, G; Pandiella, A; Richardson, PG; San-Miguel, JF; Vilanova, D, 2008) |
| "To summarize the results of treatment of multiple myeloma in the era of novel agents." | ( Bladé, J; Rosiñol, L, 2008) |
| "The initial treatment of multiple myeloma (MM) experienced a paradigm shift, in the past decade, with the introduction of novel agents such as thalidomide, lenalidomide and bortezomib, leading to improved outcomes." | ( Cheng, Z; Geng, F; Li, S; Pan, L; Wang, S; Xue, F; Yang, X, 2009) |
| "A novel treatment for multiple myeloma is bortezomib, a proteasome inhibitor that has shown significant in vitro and in vivo activity." | ( Stadtmauer, EA, 2004) |
| "The drug is indicated for treatment of multiple myeloma and other hematologic disorders and has rarely been associated with pulmonary toxicity." | ( Chen, Y; Kiatsimkul, P; Nugent, K; Raj, R, 2010) |
| "Recent advances in the treatment of multiple myeloma have resulted in improved response rates and overall survival in patients with multiple myeloma." | ( Richards, T; Weber, D, 2010) |
| "Bortezomib is now widely used for the treatment of multiple myeloma (MM); however, its action mechanisms are not fully understood." | ( Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kikuchi, J; Mitsunaga, K; Noborio-Hatano, K; Nobuyoshi, M; Ozawa, K; Shimizu, R; Wada, T, 2010) |
| "Despite recent advances in treatment, multiple myeloma (MM) remains an incurable malignancy." | ( Blanco-Prieto, MJ; Campanero, MA; de la Iglesia-Vicente, J; Estella-Hermoso de Mendoza, A; Gajate, C; Mollinedo, F; Villa-Pulgarin, JA, 2010) |
| "Lenalidomide is an active treatment for multiple myeloma (MM) and is increasingly used as part of the initial treatment of this disease." | ( Cook, R; Cunningham, K; Gardler, M; Hummel, K; Luger, SM; Mangan, PA; Nazha, A; O'Doherty, U; Porter, DL; Schuster, S; Siegel, D; Stadtmauer, EA; Vogl, DT, 2011) |
| "Bortezomib is an effective agent for treating multiple myeloma (MM)." | ( Iida, S; Inagaki, A; Ishida, T; Ito, A; Komatsu, H; Kusumoto, S; Miyazaki, H; Mori, F; Nakashima, T; Ri, M; Shiotsu, Y; Ueda, R, 2010) |
| "We show here that treatment of human multiple myeloma (MM) cells with 17DMAG induces mTOR inhibition and microtubule-associated protein light chain 3 (LC3) conversion (LC3-I to LC3-II), an indicator of autophagy." | ( López-Pérez, AI; López-Rivas, A; Martín-Pérez, R; Palacios, C; Pandiella, A, 2010) |
| "Approval of bortezomib for the treatment of multiple myeloma validated the proteasome as an anticancer target." | ( Tsukamoto, S, 2010) |
| "Until recently, standard treatment of multiple myeloma (MM) in elderly patients who were not candidates for autologous stem cell transplantation was with the combination of melphalan plus prednisone (MP)." | ( Harousseau, JL, 2010) |
| "A multicenter phase III study for untreated multiple myeloma was conducted to investigate a switch-induction chemotherapy with melphalan-prednisolone and vincristine-doxorubicin-dexamethasone followed by randomization on maintenance therapy for patients achieving plateau." | ( Ando, K; Asakawa, T; Chou, T; Fukuda, H; Hotta, T; Iida, S; Mizoroki, F; Saito, I; Tobinai, K; Tsukasaki, K; Ueda, R; Uike, N, 2011) |
| "The introduction of new agents in the treatment of multiple myeloma, such as thalidomide, bortezomib, or lenalidomide, has represented an important step forward in the management of this disease, with improvement in both treatment response and patient survival." | ( González Rodríguez, AP, 2011) |
| "The authors have reviewed the treatment of multiple myeloma including the novel agents, thalidomide, bortezomib and lenalidomide." | ( Kyle, RA; Steensma, DP, 2011) |
| "Although treatment for multiple myeloma (MM) has considerably improved in the past decade, MM continues to be an incurable hematological malignancy that causes most patients to eventually relapse and die from their illness." | ( Benevolo, G; Boccadoro, M; Botto, B; Evangelista, A; Frairia, C; Gay, F; Gentile, M; Larocca, A; Morabito, F; Palumbo, A; Pregno, P; Vitolo, U, 2011) |
| "The results showed that the sera of untreated multiple myeloma patients elevated hepcidin mRNA expression of Hep-3b cells, compared with healthy controls and iron deficiency anemia patients." | ( Duan, MH; Li, SL; Shen, T; Wang, FD; Wang, X; Wu, YJ; Zhang, JP; Zhou, DB, 2011) |
| "The success of bortezomib therapy for treatment of multiple myeloma (MM) led to the development of structurally and pharmacologically distinct novel proteasome inhibitors." | ( Anderson, KC; Chauhan, D; Kuhn, D; Orlowski, R; Raje, N; Richardson, P; Tian, Z; Zhou, B, 2011) |
| "In patients with previously untreated multiple myeloma, long-term outcome with respect to progression-free survival, overall survival, and relapse rate is superior after auto-allo compared with auto only." | ( Beksac, M; Björkstrand, B; Bosi, A; Corradini, P; de Witte, T; Gahrton, G; Goldschmidt, H; Greinix, H; Gruber, A; Hegenbart, U; Iacobelli, S; Milone, G; Morris, C; Musto, P; Narni, F; Niederwieser, D; Volin, L, 2011) |
| "The approval of bortezomib for the treatment of multiple myeloma validated the 20S core particle as an anticancer drug target." | ( Brnjic, S; D'Arcy, P; De Cesare, M; Fryknäs, M; Hassan, M; Larsson, R; Linder, S; Lindsten, K; Olofsson, MH; Perego, P; Sadeghi, B, 2011) |
| "The present studies demonstrate that treatment of multiple myeloma cells with a MUC1-C inhibitor is associated with increases in reactive oxygen species (ROS), oxidation of mitochondrial cardiolipin, and loss of the mitochondrial transmembrane potential." | ( Kosugi, M; Kufe, D; Yin, L, 2012) |
| "We report the use of thalidomide to treat multiple myeloma, and describe problems arising in the Thaled® outpatient department." | ( Aimono, Y; Aoyama, Y; Chikatsu, N; Ebata, S; Hakozaki, M; Isa, S; Kudo, D; Monma, Y; Onozaki, M; Otani, E; Saito, Y; Sato, W; Sawahata, T; Shinagawa, A; Suzuki, M, 2011) |
| "Thalidomide showed some success in treating multiple myeloma either after auto-PBSCT or following treatment with bortezomib." | ( Aimono, Y; Aoyama, Y; Chikatsu, N; Ebata, S; Hakozaki, M; Isa, S; Kudo, D; Monma, Y; Onozaki, M; Otani, E; Saito, Y; Sato, W; Sawahata, T; Shinagawa, A; Suzuki, M, 2011) |
| "Despite recent treatment advances, multiple myeloma (MM) remains incurable and patients develop a progressively relapsing disease with subsequent poor prognosis." | ( Hu, R; Li, J; Li, Y; Liao, A; Liu, Z; Wang, H; Yang, W; Yao, K; Zhang, R; Zhao, Q, 2012) |
| "One, bortezomib, is used clinically for treatment of multiple myeloma, mantle cell lymphoma, and acute allograft rejection." | ( Kisselev, AF; Overkleeft, HS; van der Linden, WA, 2012) |
| "Bortezomib was approved for the treatment of multiple myeloma (MM) in 2003." | ( Kapoor, P; Rajkumar, SV; Ramakrishnan, V, 2012) |
| "VD-DLIs is a safe treatment for multiple myeloma patients relapsing or progressing after alloSCT and may be effective." | ( Bruno, B; Corradini, P; Dodero, A; Fanin, R; Montanari, M; Montefusco, V; Mussetti, A; Offidani, M; Patriarca, F; Scortechini, I; Sperotto, A; Spina, F; Valagussa, P, 2013) |
| "Optimal salvage treatment for multiple myeloma relapsing after allogeneic stem cell transplantation remains to be determined." | ( Bachy, E; Bourhis, JH; Brebion, A; Coman, T; François, S; Hermine, O; Huynh, A; Lapusan, S; Lioure, B; Maury, S; Michallet, M; Milpied, N; Mohty, M; Rubio, MT; Socié, G; Uzunov, M; Vigouroux, S; Yakoub-Agha, I, 2013) |
| "Lenalidomide (LEN) treatment in multiple myeloma (MM) results in a superior outcome." | ( Dai, L; Gollin, SM; Lentzsch, S; Mapara, MY; Monaghan, SA; Normolle, DP, 2013) |
| "Despite recent advances in the treatment of multiple myeloma, most patients will eventually relapse, requiring further treatment." | ( Steele, JM, 2013) |
| "Many advances were made in the treatment of multiple myeloma since the introduction of the immunomodulatory drugs thalidomide and lenalidomide and the proteasome inhibitor bortezomib." | ( Mina, R; Palumbo, A, 2013) |
| "Before coming to our hospital, he was treated for multiple myeloma with cyclophosphamide." | ( Kojima, K; Shibata, Y; Takagi, K; Yuhara, K, 2012) |
| "Novel agents to treat multiple myeloma (MM) have increased complete respone (CR) rates compared with conventional chemotherapy, and the quality of the response to treatment has been correlated with survival." | ( Bae, SH; Chung, JS; Eom, HS; Jo, DY; Kim, HJ; Kim, JS; Kim, K; Kim, MK; Kim, SH; Kim, YS; Lee, HS; Lee, JH; Min, CK; Mun, YC; Suh, C; Yoon, SS, 2013) |
| "Bortezomib is commonly used in treating multiple myeloma (MM)." | ( Chen, J; Li, S; Que, W, 2013) |
| "Lenalidomide is now widely used for the treatment of multiple myeloma in virtue of its potent anti-tumor activity and low toxicity." | ( Aoki, T; Danbara, M; Higashihara, M; Katayama, T; Miyazaki, K; Tadera, N; Togano, T, 2013) |
| "Initial treatment for multiple myeloma has changed markedly." | ( Abel, GA; Harlan, LC; Little, RF; Stevens, J; Warren, JL, 2013) |
| "This case shows that successful treatment of multiple myeloma leads to marked improvement of accompanying AL amyloidosis." | ( Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S, 2013) |
| "Many advances in the treatment of multiple myeloma have been made due to the use of transplantation and the introduction of novel agents including thalidomide, lenalidomide, and bortezomib." | ( Cerrato, C; Palumbo, A, 2013) |
| "Lenalidomide is indicated for treatment of multiple myeloma in combination with dexamethasone and as a single agent in myelodysplastic syndromes." | ( Garden, BC; Lacouture, ME; Nardone, B; Reich, LM; West, DP; Wu, S, 2013) |
| "The use of new drugs has improved the treatment of multiple myeloma and diffuse large B-cell lymphoma (DLBCL)." | ( Hella, H; Holien, T; Misund, K; Olsen, OE; Rø, TB; Sundan, A; Waage, A, 2013) |
| "Progress in the treatment of multiple myeloma in the last decade has been able to delay, but ultimately not to prevent, the development of resistances and most patients still die of the disease or its related complications." | ( Motlló, C; Oriol, A, 2014) |
| "Three cost effectiveness models for the treatment of multiple myeloma, were compared that had been developed to inform resource allocation in the UK for the chemotherapy regimens bortezomib, melphalan and prednisolone (BMP); and melphalan, prednisolone and thalidomide (MPT) versus melphalan and prednisolone (MP)." | ( Bryant, J; Clegg, A; Cooper, K; Picot, J, 2014) |
| "Using models developed for assessing treatments for multiple myeloma we demonstrated that it was feasible to compare models, which then aided decision makers in making reimbursement decisions." | ( Bryant, J; Clegg, A; Cooper, K; Picot, J, 2014) |
| "Despite recent advances in the treatment of multiple myeloma (MM), it remains an incurable disease potentially due to the presence of resistant myeloma cancer stem cells (MM-CSC)." | ( Corchete, LA; Garayoa, M; García-Sanz, R; Gutiérrez, NC; Krzeminski, P; Ocio, EM; Paíno, T; Paiva, B; Redondo, A; San-Miguel, JF; San-Segundo, L; Sarasquete, ME, 2014) |
| "Although widely accepted as treatment of multiple myeloma and non-Hodgkin's lymphoma, it has also been shown to be efficacious in a variety of solid tumours such as pancreatic and colonic." | ( Nixon, NA; Parhar, K, 2014) |
| "Our results indicate that the treatment of multiple myeloma with bortezomib and dexamethasone is feasible." | ( Atsumi, M; Ito, T; Kameda, K; Kiba, T; Kido, M; Kimura, A; Miyamae, F; Nakashima, T; Niimi, H; Okikawa, Y; Shitakubo, Y; Sumitani, Y; Tanaka, S, 2014) |
| "Recent developments in the treatment of multiple myeloma have led to improvements in response rates and to increased survival; however, relapse is inevitable in almost all patients." | ( Anderson, KC; Dimopoulos, MA; Moreau, P; Richardson, PG, 2015) |
| "Ritonavir-treated multiple myeloma cells exhibited increased reliance on glutamine metabolism." | ( Adekola, KU; Bajpai, R; Dalva-Aydemir, S; Kandela, I; Koblinski, JE; Martinez, M; Raje, NS; Rosen, ST; Shanmugam, M; Singhal, S; Wei, C, 2015) |
| "Despite the recent advances in the treatment of multiple myeloma (MM), MM patients with high-risk cytogenetic changes such as t(4;14) translocation or deletion of chromosome 17 still have extremely poor prognoses." | ( Du, W; Hasegawa, Y; Hattori, Y; Hozumi, M; Ichikawa, D; Matsuo, K; Matsushita, M; Oikawa, T; Ozaki, Y; Shiheido, H; Tabata, N; Terada, F; Yamada, T; Yanagawa, H, 2015) |
| "Patients with untreated or relapsed multiple myeloma not eligible for high-dose chemotherapy followed by autologous stem cell transplantation and who were scheduled for bortezomib mono- or combination therapy or melphalan-prednisone (MP) alone were included in this study." | ( Alkemper, B; Gaede, B; Knauf, W; Reschke, D; Schlag, R; Schmits, R; Schütz, S; Schwarzer, A; Tapprich, C, 2015) |
| "Recent developments in the treatment of multiple myeloma (MM) have led to improvements in response rates and to increased survival." | ( Moreau, P; Touzeau, C, 2015) |
| "Despite many recent advances in the treatment of multiple myeloma, the course of the disease is characterized by a repeating pattern of periods of remission and relapse as patients cycle through the available treatment options." | ( Facon, T, 2015) |
| "The effectiveness of bortezomib treatment for multiple myeloma (MM) is well established." | ( Iimori, S; Nagao, T; Negi, M; Okado, T; Oshikawa, G; Rai, T; Uchida, S; Yamaguchi, W; Yui, N, 2016) |
| "Advances in the treatment of multiple myeloma have resulted in dramatic improvements in outcomes for patients." | ( Lonial, S; Nooka, AK, 2016) |
| "New drugs for the treatment of multiple myeloma (MM) comprise immunomodulatory substances such as lenalidomide and related compounds." | ( Boquoi, A; Bruns, I; Cadeddu, RP; Deenen, R; Dienst, A; Fenk, R; Haas, R; Heinzler, N; Kobbe, G; Köhrer, K; Majidi, F; Schroeder, T; Strapatsas, T; Wilk, CM, 2016) |
| "Bortezomib (BTZ) is used for the treatment of multiple myeloma (MM)." | ( Dimas, K; Liakos, P; Pangou, E; Papandreou, C; Sakellaridis, N; Vaiou, M; Vassilopoulos, G, 2016) |
| "Despite great progress made in the treatment of multiple myeloma (MM), it is still incurable." | ( Chen, Z; He, W; Huang, X; Lei, W; Liu, X; Qian, W; Shen, J; Wang, S; Yang, C, 2016) |
| "In the last decades, treatment of multiple myeloma (MM) has greatly improved due to the introduction of novel agents, including proteasome inhibitors (PI) and immunomodulatory agents (IMiDs)." | ( Delforge, M; Kint, N, 2016) |
| "Despite advances in treatment, multiple myeloma (MM) remains incurable." | ( Avigdor, A; Ben-Shushan, D; Duek, A; Jakubikova, J; Leiba, A; Leiba, M; Nagler, A; Paukov, L; Rozic, G, 2016) |
| "Despite recent advances made in its treatment, multiple myeloma (MM) remains an incurable B cell malignancy." | ( Berenson, A; Berenson, JR; David, M; Eades, B; Eshaghian, S; Gottlieb, J; Halleluyan, R; Harutyunyan, NM; Nassir, Y; Spektor, TM; Swift, R; Udd, KA; Vardanyan, S; Wang, J, 2017) |
| "The overall goal of treatment for multiple myeloma (MM) is to prolong survival for as long as possible with the minimal treatment burden for each patient." | ( Giralt, SA; Shah, GL, 2016) |
| "Patients starting a treatment for multiple myeloma in the period 2011-2014 were identified through hospital and chronic disease diagnoses." | ( Despas, F; Gauthier, M; Lapeyre-Mestre, M; Moulis, G; Palmaro, A; Rougé-Bugat, ME, 2017) |
| "High-dose chemotherapies to treat multiple myeloma (MM) can be life-threatening due to toxicities to normal cells and there is a need to target only tumor cells and/or lower standard drug dosage without losing efficacy." | ( Allamargot, C; Coleman, KL; Frech, I; Nessler, R; Tricot, G; Xia, J; Xu, H; Zhan, F; Zhang, X, 2017) |
| "Curative responses in the treatment of multiple myeloma (MM) are limited by the emergence of therapeutic resistance." | ( Dolloff, NG; Dytfeld, D; Jakubowiak, A; Komarnicki, M; Luczak, M; Manevich, Y; Mitra, AK; Przybylowicz-Chalecka, A; Reyes, L; Robinson, RM; Smith, B; Szczepaniak, T; Thompson, RM; Van Ness, BG, 2017) |
| "Despite the great progress in the treatment, multiple myeloma (MM) still remains incurable." | ( Chen, P; Cheng, Y; Hou, D; Huang, H; Wen, X; Xie, J; Yang, H; You, P; Yuan, Q, 2017) |
| "Lenalidomide has a central role in the treatment of multiple myeloma and results in improved survival." | ( Faber, LM; Kootte, RS, 2017) |
| "Despite recent advances in the treatment of multiple myeloma (MM), the prognosis of most patients remains poor, and resistance to traditional and new drugs frequently occurs." | ( Bergsagel, PL; Chesi, M; Garayoa, M; González-Díaz, M; González-Méndez, L; Gutiérrez, NC; Hernández-García, S; Herrero, AB; López-Iglesias, AA; Martín-Sánchez, M; Mateos, MV; Mehrling, T; Misiewicz-Krzeminska, I; Ocio, EM; Paíno, T; Primo, D; Quwaider, D; San-Miguel, JF; San-Segundo, L, 2017) |
| "Recent innovations in the treatment of multiple myeloma have enriched our therapeutic repertoire regarding the treatment of multiple myeloma during the last decades." | ( Schmeel, FC; Schmeel, LC; Schmidt-Wolf, IGH, 2017) |
| "Complete response (CR) after treatment for multiple myeloma is associated with superior progression-free survival (PFS)." | ( Akazawa, K; Hirano, T; Izutsu, K; Kako, S; Kamoshita, M; Kanda, J; Kanda, Y; Kurita, N; Minauchi, K; Miyaoka, E; Nakasone, H; Ota, S; Shimizu, S; Tanimoto, S; Terasako-Saito, K; Usuki, K; Wake, A; Yamamoto, G; Yamazaki, E; Yokoyama, Y, 2018) |
| "Alternatives of treatments for multiple myeloma (MM) have become increasingly available with the advent of new drugs such as proteasome inhibitors, thalidomide derivatives, histone deacetylase inhibitors, and antibody drugs." | ( Fujimori, K; Hattori, Y; Ichikawa, D; Iwasaki, G; Kitabatake, S; Kiuchi, F; Matsushita, M; Okayama, M; Sato, M; Suto, Y; Yamagiwa, N, 2017) |
| "Bortezomib is highly effective in the treatment of multiple myeloma; however, emergent drug resistance is common." | ( Ahmann, J; Braggio, E; Bruins, LA; Jedlowski, P; Kortüm, KM; Luo, M; Shi, CX; Stewart, AK; Stewart, RA; Votruba, PG; Zhu, YX, 2017) |
| "A promising approach to the treatment of multiple myeloma (MM) involves agents that target not only the myeloma cells directly, but also the tumor microenvironment which promotes tumor cell growth, angiogenesis, and MM bone disease." | ( Anderson, KC; Breitkreutz, I; Figueroa-Vazquez, V; Hayden, PJ; Podar, K; Raab, MS; Wilhelm, S, 2018) |
| "Proteasome inhibitors used in the treatment of multiple myeloma act primarily through the disruption of intrinsic cellular protein quality maintenance, resulting in proteotoxic stress, cellular dysfunction, and, ultimately, cell death." | ( Broberg, C; Ferencik, M; Heitner, SB; Medvedova, E; Minnier, J; Naher, A; Ritts, A; Scott, EC; Silbermann, R; Van Woerkom, RC, 2018) |
| "Pomalidomide, previously used to treat multiple myeloma, has been reported to cause acute pulmonary toxicity that improves with drug discontinuation." | ( Blanc, PD; Brown, JK; Callahan, EC; Elicker, B; Gajic, S; Ley, B, 2018) |
| "Multiple myeloma treatment." | ( Roussel, M; Royer, B; Talbot, A, 2018) |
| "Proteasome inhibition is an effective treatment for multiple myeloma (MM); however, targeting different components of the ubiquitin-proteasome system (UPS) remains elusive." | ( Anderson, KC; Chauhan, D; Du, T; Filippakopoulos, P; Li, D; Park, PMC; Picaud, S; Qi, J; Ray, A; Song, Y; Wimalasena, VK; Wu, L, 2019) |
| "Thalidomide is commonly used in treatment of multiple myeloma (MM)." | ( Chocholska, S; Homa-Mlak, I; Hus, M; Jankowska-Łęcka, O; Mazurek, M; Małecka-Massalska, T; Mielnik, M; Mlak, R; Szczyrek, M; Szudy-Szczyrek, A, 2019) |
| "The significant advances made in the treatment of multiple myeloma (MM) have allowed for a paradigm shift away from the early use of high-dose melphalan with autologous stem cell transplant (HDM-ASCT)." | ( Kazandjian, D; Landgren, O, 2019) |
| "Despite remarkable advances in the treatment of multiple myeloma in the last decades, the prognosis of patients harboring high-risk cytogenetic abnormalities remains dismal as compared to that of standard-risk patients." | ( Ballanti, S; Benevolo, G; Boccadoro, M; Bonello, F; Bringhen, S; Capra, A; Cavo, M; Conticello, C; Gaidano, G; Galieni, P; Gilestro, M; Liberati, AM; Mina, R; Montefusco, V; Musto, P; Olivieri, A; Omedé, P; Palumbo, A; Petrucci, MT; Siniscalchi, A, 2021) |
| "Future progress in the treatment of multiple myeloma (MM) requires both the characterisation of key drivers of the disease and novel, innovative approaches to tackle these vulnerabilities." | ( Bolomsky, A; Branstrom, A; Breid, H; Caers, J; Duray, E; Hübl, W; Lejeune, M; Ludwig, H; Muller, J; Pfeiffer, C; Stangelberger, K; Vrancken, L; Weetall, M; Willheim, M; Zojer, N, 2020) |
| "Lenalidomide is a backbone agent in the treatment of multiple myeloma, but dose adjustment is required for those with renal impairment (RI)." | ( Cao, Y; Chen, CI; Chen, E; Chen, H; Kakar, S; Kukreti, V; Lau, A; Le, LW; Levina, O; Paul, H; Prica, A; Reece, DE; Tiedemann, R; Trudel, S, 2020) |
| "Despite the advances in the treatment of multiple myeloma (MM), complete remission is usually challenging." | ( Asghari, MH; Moloudizargari, M; Mortaz, E; Mosaffa, N; Redegeld, F, 2020) |
| "Isatuximab is used to treat multiple myeloma (MM), characterized by the excessive production of abnormal "myeloma proteins" (M-proteins) that may interact with therapeutic IgG mAb on the neonatal Fc receptor (FcRn)-mediated recycling pathway." | ( Brillac, C; Campana, F; El-Cheikh, R; Fau, JB; Koiwai, K; Mace, N; Nguyen, L; Semiond, D, 2020) |
| "Carfilzomib was approved for the treatment of multiple myeloma in 2012 and since then there have been concerns for cardiovascular toxicity from its use." | ( Bian, J; Bishnoi, R; Farhadfar, N; Murthy, HS; Shah, C; Wingard, JR; Xie, Z, 2021) |
| "It is part of first line treatment for multiple myeloma when combined with lenalidomide and dexamethasone." | ( Dougherty, JA; Elder, CT, 2022) |
| "Carfilzomib is mainly used to treat multiple myeloma." | ( Chu, TH; Jung, SH; Kim, C; Kim, JY; Lee, C; Lee, JJ; Mai, TT; Vo, MC, 2021) |
| "The plateau phase emerging during the treatment of multiple myeloma (MM) is known to last steadily for a certain period, even without treatment." | ( Fuchida, SI; Hino, M; Imada, K; Ishikawa, J; Ito, T; Kanakura, Y; Kanda, J; Kaneko, H; Karasuno, T; Kawata, E; Kosugi, S; Kuroda, J; Matsumura, I; Nakatani, E; Nomura, S; Ohta, K; Shibano, M; Shibayama, H; Shimazaki, C; Shimizu, Y; Shimura, Y; Shindo, M; Takakuwa, T; Takaori-Kondo, A; Tanaka, H; Uchiyama, H; Uoshima, N; Yagi, H, 2021) |
| "Despite the significant advances in the treatment of multiple myeloma (MM), this disease is still considered incurable because of relapse and chemotherapy resistance, underscoring the need to seek novel therapies with different mechanisms." | ( Bu, Z; Cao, Y; Fang, Z; Gu, W; Ji, Y; Lei, H; Liu, J; Liu, M; Liu, W; Liu, Y; Shan, H; Wu, Y; Xu, H; Xu, X; Yan, H; Yu, M; Zhang, X; Zhang, Z, 2021) |
| "Advances in the understanding and treatment of multiple myeloma have led to the need for more sensitive and accurate imaging of intramedullary and extramedullary disease." | ( Bernard, S; Fayad, LM; Ilaslan, H; Messiou, C; Moulopoulos, LA; Mulligan, ME; Wu, F, 2021) |
| "With major advancements in treatments for multiple myeloma (MM), it is critical that we evaluate our methods for both diagnosing MM and monitoring its progression over time." | ( O'Donnell, EK; Shapiro, YN, 2022) |
| "Addition of XVd to the previously treated multiple myeloma treatment landscape provides a novel oral treatment option, which, when compared to Vd in the base-case analysis resulted in an incremental cost-effectiveness ratio of $475,430/QALY." | ( Dolph, M; Leong, H; Tremblay, G, 2021) |
| "Major developments in the treatment of multiple myeloma (MM) over the past decade have led to a continued improvement in survival." | ( Goel, U; Kumar, S; Usmani, S, 2022) |
| "Carfilzomib (Cfz) is widely used to treat multiple myeloma." | ( Fukumoto, A; Ikeda, D; Kuzume, A; Matsue, K; Miura, D; Narita, K; Tabata, R; Takeuchi, M; Terao, T; Tsushima, T, 2022) |
| "Immense progress has been made for the treatment of multiple myeloma over the past two decades, with patient outcomes improving dramatically as a result." | ( Franz, J; Myrus, E; Richter, J; Sanchez, L, 2023) |
| "IT848 treatment of multiple myeloma cell lines and patient samples inhibited proliferation and induced caspase-dependent and independent apoptosis." | ( Bariana, M; Cassella, E; Colorado, I; Feinman, R; Heller, C; Heller, G; Liou, HC; Makhdoom, A; Mondello, P; Ouk, S; Rateshwar, J; Siegel, DS; Tuckett, A; Zakrzewski, JL, 2022) |
| "Under the selective pressure of PI treatment, multiple myeloma cells acquire methylation of the PSMD5 promoter silencing the PSMD5 gene expression." | ( Barrio, S; Bolli, N; Da Viá, M; Einsele, H; Fernandez, RA; Garitano-Trojaola, A; Haaf, T; Haertle, L; Haferlach, C; Hajek, R; Han, S; Kortüm, KM; Martinez-Lopez, J; Munawar, U; Nerreter, S; Raab, MS; Raab, P; Rasche, L; Rosenwald, A; Ruiz-Heredia, Y; Simicek, M; Snaurova, R; Steinhardt, M; Teufel, E; Truger, M; Vogt, C; Weingart, J; Weinhold, N; Zhou, X, 2023) |
| "Bortezomib, which is widely used in the treatment of multiple myeloma (MM), is a proteasome inhibitor and acts by inducing apoptosis." | ( Çeneli, Ö; Kars, TU; Yaşkıran, O, 2023) |
| "Bortezomib, which is widely used in the treatment of multiple myeloma (MM), is a proteasome inhibitor and acts by inducing apoptosis." | ( Çeneli, Ö; Kars, TU; Yaşkıran, O, 2023) |
| "A 72-years-old male, treated for multiple myeloma with dexamethasone, pomalidomide and daratumumab, presented dyspnea, hypoxemia, biological inflammatory syndrome, ground glass opacities on computed tomography scan (CT-scan) and lymphocytic and eosinophilic alveolitis, with no specific cytologic or microbiological findings, 2 months after pomalidomide initiation." | ( Ancel, J; Deslee, G; Dury, S; Godet, S; Launois, C; Perotin, JM; Vivien, A, 2023) |
| "Lenalidomide is commonly used for treatment of multiple myeloma (MM) as well as other hematological disorders." | ( Ali, SB; Hissaria, P; Horvath, N; Le, TA; Lee, WI; Smith, W, 2023) |
| "Bortezomib has been successful for treatment of multiple myeloma, but not against solid tumors, and toxicities of neuropathy, thrombocytopenia and the emergence of resistance have triggered efforts to find alternative proteasome inhibitors." | ( Anchoori, RK; Anchoori, V; Chang, YN; Das, S; Karanam, B; Lam, B; Patnam, R; Poddatoori, D; Roden, RBS; Rudek, MA; Tseng, SH; Velasquez, FC, 2023) |